
 
 
 
 
 
 
 
 
 Composition comprising bacterium bacterial strain 
 
 Technical field 
 The present invention relates to the compositions of the bacterium bacterial strain comprising separating from mammalian digestive tract and such composition to exist
The field for treating the purposes in disease. 
 
 
 Background technique 
 Human intestine is considered in uterus being sterile, but it is immediately exposed to various mothers after birth
Body and environmental microorganism.Then, the microorganism that dynamic time section occurs colonizes and multiplies, this is influenced by factor such as below:
Childbirth options, environment, diet and host gene type, all these all influence the composition of intestinal microbiota, in the primordial growth traits phase
Between it is especially true.Then, micropopulation stabilizes and becomes mature [1].Human intestinal microorganisms group is containing more than 1500 kinds
Different phylotype, the main division bacteria of two of them (door) occupy leading position on abundance level: Bacteroidetes and thickness
Wall bacterium door [2].By human intestine bacterial colonization generate successful symbiosis generated various metabolism, structure,
Protectiveness and other beneficial functions.The metabolic activity of the enhancing of the enteron aisle colonized ensures the meals for being otherwise difficult to digest
Food component is degraded with the release of by-product, to provide important nutriment source and other health benefit for host
Place.Similarly, the immunology importance of intestinal microbiota is fully recognized and is illustrated in germfree animal, described sterile
Animal has the compromised immune system [3-5] functionally reconstructed after introducing symbiotic bacteria. 
 The dynamic change of micropopulation composition has had in gastrointestinal disorder such as inflammatory bowel disease (IBD) recorded.For example, shuttle
The level of bacterium (Clostridium) cluster XIVa bacterium reduces in IBD subject, and the quantity of Escherichia coli (E.coli) increases
Add, to show the variation [6-9,18] of enteron aisle endosymbiosis biology and causal organism balance. 
 After recognizing the potential positive effect that certain bacterium bacterial strains may have animal intestinal tract, it has been suggested that various
Bacterial strain is for treating various diseases (see, e.g. [10-13]).Having proposed a variety of bacterial strains (mainly includes lactobacillus
(Lactobacillus) and Bifidobacterium (Bifidobacterium) bacterial strain) for treat various enteropathies (for summary ginseng
See [14], and referring to [15]).Bibliography [16] proposes to use using the bacterial strain of Blaw spy Bordetella (genus Blautia)
In the microbial balance for adjusting the digestion ecosystem.In the context of bibliography 16, adjusting refers to that promotion produces acetic acid bacteria
The activity of damage of the flora for methane phase and sulphur reducing bacteria.Therefore, this document only instructs the increase for producing acetic acid bacteria.No
It is related to belonging to the multifarious discussion of strain of a variety of taxons.Bibliography [17] discuss using Blaw spy Salmonella for improve by
The survival rate for the patient that graft versus host disease (GVDH) influences.It mentions increased Phylogenetic diversity of bacteria and reduced GVDH phase
It is associated to close the death rate, and the increased amount of bacteria of Blaw spy Bordetella is associated with the GVDH of reduction.However, not indicating
The stabilization that Blaw spy Salmonella realizes micropopulation in the multifarious increase of micropopulation and/or induction subject is applied to patient
Property. 
 Relationship and specific bacteria bacterial strain between different bacterium bacterial strain and various disease is for enteron aisle and in systemic water
Flat lower and for any certain types of disease accurate effect do not characterized well, and at present the result is that can be changed
And compared to furnishing an answer, [18] are more led to the problem of. 
 The characteristics of changing relevant many human diseases to micropopulation is the multifarious loss of micropopulation.Such as from so-called
Flora imbalance (compared with the typical aggregation micropopulation in health volunteer, this is only the micropopulation composition changed) it is obvious
Find out, the multifarious loss of micropopulation can pass through division bacteria in sample based on sequence or activity classification unit (OTU)
Measurable reduction of quantity quantifies, and is usually determined by 16S rRNA amplicon PCR sequencing PCR.Multifarious loss is also logical
The reduction of Shannon diversity index (Shannon Diversity Index) or Chao index (Chao index) is crossed to measure.
Reduced micropopulation diversity is in obesity, inflammatory bowel disease (IBD), intestinal irritable syndrome (IBS), diabetes B and weak
The elderly current research in reported [20].Re-establishing healthy micropopulation may be difficult, because in enteron aisle
Bacterium resist colonize.When attempting micropopulation of the diversity by increasing micropopulation to handle non-health subject,
This can generate challenge [19].The adjoint property of microbial metabolism function lose be considered as these pathophysiological conditions facilitate because
Element.The normal adults stable compared to wherein micropopulation, non-health subject is such as with those of IBD, IBS and weak
The micropopulation of aged subjects is unstable [18,20]. 
 It needs to characterize the latent effect of enteric bacteria, so that the new treatment using enteric bacteria can be developed. 
 
 
 Summary of the invention 
 The present inventor developed for being treated by increasing or maintaining the intestinal microbial group diversity in subject and
The new treatment for preventing disease and illness.Specifically, present inventors have recognized that the bacterium bacterial strain from Blaw spy Bordetella can have
Imitate the quantity and/or the uniformity of different types of bacterium in the distal gut of Yu Zengjia or maintenance subject.As in embodiment
It is described, the composition comprising hydrogen nutrition Blaw spy Salmonella (Blautia hydrogenotrophica) is administered orally and increases excrement
In micropopulation diversity.This diversity increase is seen in health and IBS subject.However, the IBS for receiving placebo is tested
Person reduces during research process with statistically significant microorganism group diversity.In addition, embodiment is shown with comprising hydrogen
The micropopulation that the processing that the composition of nutrition Blaw spy Salmonella carries out increases IBS subject in entire research process is stablized
Property, but the processing carried out with placebo is not such.Receive the subject's of the composition comprising hydrogen nutrition Blaw spy Salmonella
Micropopulation stability is suitable with the micropopulation stability of normal healthy controls subject. 
 Therefore, in the first embodiment, the present invention provides a kind of combination of bacterium bacterial strain comprising Blaw spy Bordetella
Object is used to increase or maintain the multifarious method of micropopulation.Similarly, also provide it is a kind of increase or maintenance subject it is micro-
The multifarious method of biota comprising use the bacterium bacterial strain of Blaw spy Bordetella. 
 Term " increasing or maintain micropopulation diversity " is herein for meaning increase or maintaining micro- life of subject
The quantity of different types of bacterium and/or the uniformity of different types of bacterium in object group.In some embodiments, microorganism
Group's diversity increases.In some embodiments, the quantity that bacterium different in micropopulation belongs to increases.In some embodiments
In, the quantity of different bacteria cultures increases in micropopulation.In some embodiments, bacterium bacterium different in micropopulation
The quantity of strain increases.In some embodiments, micropopulation diversity is maintained.In some embodiments, micropopulation
The quantity that middle different bacterium belongs to is maintained.In some embodiments, the quantity quilt of bacteria culture different in micropopulation
It maintains.In some embodiments, the quantity of bacterium bacterial strain different in micropopulation is maintained.In some embodiments,
Belong in micropopulation, the quantity increase or maintenance of strain and bacterial strain. 
 The multifarious increase of micropopulation can be for non-production acetic acid bacteria.It may also is that for acetic acid and non-production is produced
Acetic acid bacteria.Such bacterium is well known in the art.In brief, it produces acetic acid bacteria and generates acetate as anaerobic respiration
Or the final product of fermentation. 
 In some embodiments, the multifarious loss of micropopulation, increase or maintenance can be respectively by being based in sample
Measurable reduction, increase or the maintenance of the quantity of the division bacteria or activity classification unit (OTU) of sequence are usually logical to quantify
16S rRNA amplicon PCR sequencing PCR is crossed to determine.In some embodiments, multifarious loss can be referred to by Shannon diversity
Several or Chao index reduction measures.On the contrary, in some embodiments, multifarious increase can pass through Shannon multiplicity
The increase of sex index or Chao index measures.Similarly, in some embodiments, multifarious maintenance can be more by Shannon
Sample sex index or the identical result of Chao index measure. 
 In some embodiments, the uniformity of different types of bacterium increases.In some embodiments, it is sent out with this
After bright composition is treated or prevented, the relative abundance of different types of bacterium becomes more evenly in micropopulation. 
 The present inventor has also been developed for treating and preventing disease and disease by inducing the stability of intestinal microbial group
The new treatment of disease.Specifically, present inventors have recognized that the bacterium bacterial strain from Blaw spy Bordetella induces intestinal microbial group
Stability." induction stability " means that micropopulation diversity keeps the relative populations stablized and do not belonged in micropopulation
Also it keeps stablizing.This is important, because a variety of diseases and illness (including IBS and IBD) are stablized by reduced micropopulation
Property characterizes.As described in embodiment, it is administered orally micro- in the composition induction excrement comprising hydrogen nutrition Blaw spy Salmonella
Biota stability.Therefore, in another embodiment, the present invention provides a kind of bacterium bacterial strain comprising Blaw spy Bordetella
Composition, the method for being used to induce the micropopulation stability of subject.Similarly, a kind of induction subject is also provided
The method of micropopulation stability comprising use the bacterium bacterial strain of Blaw spy Bordetella. 
 In some embodiments, in such as diagnosis with the disease or illness that feature is that micropopulation diversity reduces
After being treated or prevented in subject with composition of the invention, the phase of different bacterium strain in the micropopulation of subject
Logarithm amount becomes more stable.In some embodiments, in such as diagnosis with the disease that feature is that micropopulation diversity reduces
It is different thin in the micropopulation of subject after being treated or prevented in the subject of disease or illness with composition of the invention
The relative populations of Pseudomonas become more stable.The stability of the micropopulation of subject can pass through the ratio at two different time points
It is evaluated compared with the microorganism group from subject.If there is microorganism group difference, then this can indicate that disease or illness exist.?
In some embodiments, two different time points are separated by least three days (for example, being separated by least 1 week, 2 weeks, January, March, 6
The moon, 1 year, 2 years).In some embodiments, two different time points are separated by 3-7 days, are separated by 1-2 weeks, being separated by 2-4 weeks, phase
Every 4-8 weeks, be separated by 8-24 weeks, be separated by 24-40 weeks, be separated by 40-52 weeks or be separated by more than 52 weeks.In some embodiments, make
With more than two different time point, such as three, four, five or it is more than five time points.Suitably it is spaced in for example such as
It was selected between upper listed various time points. 
 In the preferred embodiment of all aspects of the invention, bacterium bacterial strain be hydrogen nutrition Blaw spy Salmonella and preferably
Ground is with the bacterium of 10507/14294 preservation of accession number DSM. 
 In some embodiments, micropopulation diversity and/or micropopulation stability refer in the excrement of subject
Micropopulation diversity and/or stability.In some embodiments, micropopulation diversity and/or micropopulation are stablized
Property refers to micropopulation diversity and/or stability in the fecal specimens from subject.In some embodiments, micro- life
Object group diversity and/or micropopulation stability refer to micropopulation diversity and/or stabilization in the distal gut of subject
Property.In some embodiments, micropopulation diversity and/or micropopulation stability refer to micro- in the gastrointestinal tract of subject
Biota diversity and/or stability.In some embodiments, micropopulation diversity and/or micropopulation stability are
Refer to the micropopulation diversity and/or stability in caecum.In some embodiments, micropopulation diversity and/or micro- life
Object group's stability refers to micropopulation diversity and/or stability in colon. 
 In some embodiments, the present invention provides a kind of composition of bacterium bacterial strain comprising Blaw spy Bordetella,
It is horizontal related to the micropopulation diversity of the micropopulation diversity reduction relative to health volunteer for treating or preventing
The method of the disease or illness of connection.In some embodiments, composition of the invention is used to be treated or prevented so that micro-
Biota diversity increases to level present in healthy individuals.In some embodiments, using composition of the invention into
Row treats or prevents so that micropopulation diversity increases to greater than present in some healthy individuals the level of those.Some
In embodiment, healthy individuals are similar with the age of subject/identical, and/or to subject be similar/identical race
Class.Similarly, it is reduced the present invention also provides a kind for the treatment of or prevention with the micropopulation diversity relative to health volunteer
The method of the horizontal associated disease of micropopulation diversity or illness, wherein including Blaw spy Salmonella the method includes application
The composition of the bacterium bacterial strain of category.Example with the horizontal associated disease of reduced micropopulation diversity or illness include but
Be not limited to: IBS, IBD [21], obesity [22], diabetes B, infectious diseases, allergic disease, autoimmune disease with
And metabolic disease/illness.The present invention covers the treatment or prevention of these diseases and illness.In some embodiments, the disease
Disease or illness are IBS. 
 In some embodiments, subject is more with reduced micropopulation compared with healthy babies or children respectively
The baby or children of sample.It has been observed that there is drop as 1 week big baby in some children that later stage of life suffers from allergic disease
Low excreta micropopulation diversity [23].Therefore, in some embodiments, the baby is large and small less than 1 week in 2 weeks
It is large and small large and small in two months big or big less than April January.In some embodiments, subject is not pass through vaginal delivery
The baby of birth.For example, in some embodiments, subject is the baby by caesarean deliveries.Reduced micropopulation
Diversity has also been reported in weak aged subjects.Therefore, in some embodiments, subject is aged subjects,
Such as weak aged subjects.In some embodiments, the age of subject is 65 years old or bigger (for example, the age is 70
Year or bigger, 75 years old or bigger, 80 years old or bigger, 85 years old or bigger or 90 years old or bigger) [20]. 
 It is estimated that single human individual has about 101 kinds of different bacteria cultures and 195 kinds not in its micropopulation
Same bacterial strain [24].Therefore, in some embodiments, the composition for treat in its micropopulation having less than
101 kinds of different bacteria cultures are (for example, be less than 100,99,98,97,96,95,94,93,92,91,90,85,80,75 or 70
Kind of bacteria culture) and/or less than 195 kinds different bacterial strains (for example, less than 194,193,192,191,190,189,188,
187,186,185,183,180,175,170,165,160,150,140 kind of bacterium bacterial strain) subject.In some embodiment party
In case, it is described treat or prevent so that micropopulation diversity increase to more than 80 kinds bacteria cultures (for example, more than 85,90,
91,92,93,94,95,96,97,98,99 or 100 kind of bacteria culture) or increase to 101 kinds of bacteria cultures.For example, in some realities
It applies in scheme, the treatment or prevention are so that micropopulation diversity increases to more than 90 kinds bacteria cultures.For example, in some realities
It applies in scheme, the treatment or prevention are so that micropopulation diversity increases to more than 95 kinds bacteria cultures.For example, some
In embodiment, the treatment or prevention are so that micropopulation diversity increases to more than 97 kinds bacteria cultures.For example, some
In embodiment, the treatment or prevention are so that micropopulation diversity increases to more than 99 kinds bacteria cultures.In some implementations
In scheme, it is described treat or prevent so that micropopulation diversity increase to more than 160 kinds bacterium bacterial strains (for example, more than 165,
170,185,186,187,188,189,190,191,192,193 or 194 kind of bacteria culture) or increase to 195 kinds of bacterium bacterium
Strain.For example, in some embodiments, the treatment or prevention are so that micropopulation diversity increases to more than 175 kinds bacteriums
Bacterial strain.For example, in some embodiments, it is described to treat or prevent so that micropopulation diversity increases to thin more than 185 kinds
Bacteria strain.For example, in some embodiments, the treatment or prevention are so that micropopulation diversity is increased to more than 190 kinds
Bacterium bacterial strain. 
 In some embodiments, described to treat or prevent so that micropopulation diversity increases at least one bacterium category
(for example, at least two, three kind, four kinds, five kinds, six kinds, seven kinds, eight kinds, nine kinds or ten kinds of bacterium categories).In some embodiments
In, it is described to treat or prevent so that micropopulation diversity increases at least one bacteria culture (for example, at least two, three kind, four
Kind, five kinds, six kinds, seven kinds, eight kinds, nine kinds, ten kinds, 12 kinds, 15 kinds, 17 kinds or 20 kinds of bacteria cultures).In some embodiments
In, it is described to treat or prevent so that micropopulation diversity increases at least one bacterium bacterial strain (for example, at least two, three kind, four
Kind, five kinds, six kinds, seven kinds, eight kinds, nine kinds, ten kinds, 12 kinds, 15 kinds, 17 kinds, 20 kinds or 25 kinds of bacterium bacterial strains). 
 In some embodiments, the present invention provides a kind of composition of bacterium bacterial strain comprising Blaw spy Bordetella,
For treating or preventing and the micropopulation stability (or group compared to health volunteer) compared to health volunteer
The method of the reduced associated disease of micropopulation stability or illness." reduced micropopulation stability " means microorganism
Group's diversity maintains to stablize simultaneously unlike the stability observed in health volunteer or in the group of health volunteer
And the relative populations not belonged in micropopulation do not remain stable yet.In some embodiments, inducing microbial group stability
So that stability is induced to and the similar level in health volunteer or in the presence of the group of health volunteer.Some
In embodiment, inducing microbial group's stability make stability be induced to in health volunteer or the group of health volunteer
Identical level in the presence of body.Similarly, the present invention provides a kind for the treatment of or prevention and reduced micropopulation stability
The method of associated disease or illness, wherein the method includes applying the combination of the bacterium bacterial strain comprising Blaw spy Bordetella
Object.For example, pathogenetic feature of some diseases or illness is reduced micropopulation stability.Such disease and illness
Example is IBS, IBD, diabetes (for example, diabetes B), allergic disease, autoimmune disease and metabolic disease/disease
Disease.Therefore, in some embodiments, the present invention provides a kind of composition of bacterium bacterial strain comprising Blaw spy Bordetella,
Method for treating or preventing disease associated with reduced micropopulation stability or illness, wherein the treatment or pre-
Anti- includes inducing microbial group stability.In some embodiments, the disease or illness are selected from IBS, IBD, diabetes
(for example, diabetes B), allergic disease, autoimmune disease and metabolic disease/illness.In some embodiments, institute
It states disease or illness is IBS or IBD.In some embodiments, the disease or illness are IBS.Therefore, in some implementations
In scheme, the present invention provides a kind of composition of bacterium bacterial strain comprising Blaw spy Bordetella, be used to treat or prevent IBS or
The method of IBD, wherein described treat or prevent includes inducing microbial group stability. 
 In some embodiments, the present invention provides a kind for the treatment of or prevention and the micropopulation relative to health volunteer is more
The method of the horizontal associated disease of the micropopulation diversity that sample reduces or illness, wherein the method includes by subject
Be diagnosed as it is horizontal with reduceds micropopulation diversity and then if it find that there is reduced diversity level, then to by
The composition of bacterium bacterial strain of examination person's application comprising Blaw spy Bordetella. 
 In some embodiments, it is steady with the micropopulation relative to health volunteer that the present invention provides a kind for the treatment of or prevention
The method of the qualitative reduced associated disease of micropopulation stability or illness, wherein the method includes diagnosing subject
For with reduced micropopulation stability and then if it find that then including to subject's application in the presence of reduced stability
The composition of the bacterium bacterial strain of Blaw spy Bordetella. 
 In a preferred embodiment of the present invention, the bacterium bacterial strain in composition is hydrogen nutrition Blaw spy Salmonella.May be used also
Using the bacterial strain being closely related, the 16s rRNA sequence such as with the bacterium bacterial strain with hydrogen nutrition Blaw spy Salmonella is at least
97%, the bacterium bacterial strain of the identical 16s rRNA sequence of 98%, 99%, 99.5% or 99.9%.Preferably, the bacterium bacterial strain
With with SEQ ID NO:5 at least 97%, 98%, 99%, 99.5% or 99.9% identical 16s rRNA sequence.Preferably,
The bacterium bacterial strain has the 16s rRNA sequence of SEQ ID NO:5.It is highly preferred that the bacterium bacterial strain in composition is to log in
Hydrogen nutrition Blaw spy's Salmonella bacterial strain of number 10507/14294 preservation of DSM. 
 In other embodiments of the invention, the bacterium bacterial strain in composition is excrement Blaw spy Salmonella (Blautia
stercoris).The bacterial strain being closely related, such as 16s with the bacterium bacterial strain with excrement Blaw spy Salmonella also can be used
The bacterium bacterial strain of rRNA sequence at least 97%, 98%, 99%, 99.5% or 99.9% identical 16s rRNA sequence.It is preferred that
Ground, the bacterium bacterial strain have and SEQ ID NO:1 or 3 at least 97%, 98%, 99%, 99.5% or 99.9% identical 16s
RRNA sequence.Preferably, sequence identity is for SEQ ID NO:3.Preferably, for bacterium bacterial strain of the invention have by
The 16s rRNA sequence that SEQ ID NO:3 is indicated. 
 In other embodiments of the invention, the bacterium bacterial strain in composition is Webster Blaw spy Salmonella (Blautia
wexlerae).The bacterial strain being closely related, such as the 16s rRNA with the bacterium bacterial strain with Webster Blaw spy Salmonella also can be used
The bacterium bacterial strain of sequence at least 97%, 98%, 99%, 99.5% or 99.9% identical 16s rRNA sequence.Preferably, described
Bacterium bacterial strain has and SEQ ID NO:2 or 4 at least 97%, 98%, 99%, 99.5% or 99.9% identical 16s rRNA sequence
Column.Preferably, sequence identity is for SEQ ID NO:4.Preferably, have for bacterium bacterial strain of the invention by SEQ ID
The 16s rRNA sequence that NO:4 is indicated. 
 In certain embodiments, composition of the invention is for being administered orally.The oral administration of bacterial strain of the invention can
Effective in increasing micropopulation diversity and/or inducing microbial group's stability.In addition, being administered orally for subject and working
Personnel are convenient and allow to be delivered to partially or completely colonizing for intestines and/or intestines. 
 In certain embodiments, composition of the invention includes one or more pharmaceutically acceptable excipient or load
Body. 
 In certain embodiments, composition of the invention includes the bacterium bacterial strain being lyophilized.Freeze-drying is a kind of for making
Effective and convenient technology of the standby stabilization composition for allowing bacterial delivery, and show and effective combination is provided in embodiment
Object. 
 In certain embodiments, the present invention provides a kind of food product comprising composition as described above. 
 In certain embodiments, the present invention provides a kind of vaccine composition comprising composition as described above. 
 In addition, the present invention provide a kind of increase micropopulation diversity and/or inducing microbial group stability and to
It treats or prevents and reduced micropopulation diversity and/or disease associated with reduced micropopulation stability or illness
Method comprising application comprising Blaw spy Bordetella bacterium bacterial strain composition. 
 
 
 Detailed description of the invention 
 Fig. 1: the comparison of health and the micropopulation in IBS patient. 
 Fig. 2: healthy and IBS patient micro- between the 16th day and the 1st day after with BlautiX or placebo treatment
The multifarious comparison of biota. 
 Fig. 3: A) microorganism group of the healthy patients on day 1, at the end of the 16th day and research after BlautiX processing
Interconnectivity, B) on day 1, the 16th day and research at the end of BlautiX processing after IBS patient microorganism group interconnection
Property.The healthy individuals presented in figure 3 a the interconnectivity result seen also exists respectively on day 1, at the end of the 16th day and research
It is shown in Fig. 3 A1, Fig. 3 A2 and Fig. 3 A3.The IBS patient presented in figure 3b on day 1, the 16th day and research at the end of see
To interconnectivity result also shown in Fig. 3 B1, Fig. 3 B2 and Fig. 3 B3 respectively. 
 Fig. 4: in A) the 16th day and the 1st day, B) research terminate and the 1st day and C) research terminates and at the 16th day, with
BlautiX or the placebo treatment instable comparison that the micropopulation of health and IBS patient are distributed later. 
 Fig. 5: the multifarious ratio of micropopulation after BlautiX is handled at healthy and IBS patient different time points
Compared with. 
 Fig. 6: A) on day 1, the 16th day and research at the end of BlautiX processing after healthy patients alternative net
Network, B) on day 1, the 16th day and research at the end of BlautiX processing after IBS patient alternative network.In fig. 6
The healthy individuals of presentation on day 1, at the end of the 16th day and research the alternative result seen also respectively in Fig. 6 A1, figure
It is shown in 6A2 and Fig. 6 A3.The IBS patient presented in fig. 6b on day 1, the mutual exclusion seen at the end of the 16th day and research
Property result is also shown in Fig. 6 B1, Fig. 6 B2 and Fig. 6 B3 respectively. 
 Fig. 7: the hierarchical cluster of micropopulation. 
 Fig. 8: (D14) and the micropopulation of (D32) later before the Blautix processing based on Bray-Curtis distinctiveness ratio
The comparison of distribution. 
 Fig. 9: (A) is based on Bray-Curtis distinctiveness ratio, is distributed using the micropopulation of the difference group in D-14 of PCoA
Visualization.(B) it is based on Bray-Curtis distinctiveness ratio, uses the visualization of the micropopulation distribution of each group in D14 of PCoA.
(C) significant difference (p value=0.002) of the micropopulation distribution of Blautix group is seen across time point. 
 Figure 10: being based on Bray-Curtis distinctiveness ratio, the Blautix processing at search time point (D-14, D-1, D34)
Micropopulation distribution comparison. 
 
 
 Specific embodiment 
 Bacterium bacterial strain 
 Composition of the invention includes the bacterium bacterial strain of Blaw spy Bordetella.The bacterial strain that embodiment proves that this belongs to can be used for increasing
Add micropopulation diversity and/or reduces micropopulation stability.Preferred bacterium bacterial strain is hydrogen nutrition Blaw spy Salmonella, excrement
Blaw spy Salmonella and Webster Blaw spy's Salmonella strain.More preferably hydrogen nutrition Blaw spy Salmonella, specifically with accession number DSM
The bacterium of 10507/14294 preservation. 
 Example for Blaw spy's Bordetella bacterial strain of the invention includes hydrogen nutrition Blaw spy Salmonella, excrement Blaw Te Shi
Bacterium, excrement Blaw spy Salmonella (B.faecis), spherical Blaw spy Salmonella (B. coccoides), B.glucerasea, Han Shi Blaw
Special Salmonella (B.hansenii), B.luti, mucus Eubacterium (B.producta), B.schinkii and Webster Blaw Te Shi
Bacterium.Blaw spy's Bordetella strain is the non-athletic property bacterium of the Gram-reaction positive, the bacterium can be coccus forms or ovum
Shape, and all of which is the obligate anaerobe [25] for generating acetic acid as the major end products of glucose fermentation.Blaw is special
Bordetella can separate from human intestine, although mucus Eubacterium is separated from septicaemia sample. 
 (previously known be thermophilic hydrogen Ruminococcus (Ruminococcus to hydrogen nutrition Blaw spy Salmonella
Hydrogenotrophicus it)) is separated from the enteron aisle of animal, is strictly anaerobic, and by H 2 /CO 2 It is metabolized as acetate, this
Human nutrition and health can be important.The Strain type of hydrogen nutrition Blaw spy Salmonella is S5a33=DSM 10507=
JCM 14656.The GenBank accession number of the 16S rRNA gene order of hydrogen nutrition Blaw spy's Salmonella bacterial strain S5a36 is
X95624.1 (disclosed herein is SEQ ID NO:5).This exemplary hydrogen nutrition Blaw spy Salmonella bacterial strain is in [25] and [26]
Description.S5a33 bacterial strain and S5a36 bacterial strain correspond to two of the acetogen strain separated from the faecal samples of health volunteer
Subclone.They show identical form, physiology and metabolism and 16S rRNA sequence having the same.Therefore, in some realities
It applies in scheme, there is the 16s rRNA sequence of SEQ ID NO:5 for hydrogen nutrition Blaw spy Salmonella of the invention. 
 Exist with accession number DSM 10507 and also with the hydrogen nutrition Blaw spy Salmonella bacterium of 14294 preservation of accession number DSM
Test and also referred to as BH bacterial strain in embodiment.BH bacterial strain is on May 10th, 2001 with accession number DSM 10507
And also with accession number DSM 14294 in Mikroorganismen collection (Deutsche Sammlung von
Mikroorganismen) [German Organism Depositary ([German Microorganism Collection])]
(Mascheroder Weg 1b, 38124 Brunswicks, Germany) preservation is " thermophilic hydrogen Ruminococcus ".Bailor is INRA
Laboratoire de Microbiologie CR de Clermont-Ferrand/Theix 63122Saint Gen√®s
Champanelle, France.Preservation is that the ownership of the bacterium of DSM 10507 and DSM 14294 is transmitted to 4D by transferring the possession of
Pharma Plc company. 
 Excrement Blaw spy's Salmonella bacterial strain GAM6-1 T The GenBank accession number of 16S rRNA gene order be HM626177
(disclosed herein is SEQ ID NO:1).The description in [27] of exemplary excrement Blaw spy Salmonella bacterial strain.Webster Blaw spy Salmonella
Strain type be WAL 14507=ATCC BAA-1564=DSM 19850 [25].Webster Blaw spy's Salmonella bacterial strain WAL
The GenBank accession number of the 16S rRNA gene order of 14507T is EF036467 (disclosed herein for SEQ ID NO:2).
The description in [25] of this exemplary Webster Blaw spy Salmonella bacterial strain. 
 Preferred excrement Blaw spy's Salmonella bacterial strain is with the bacterial strain of 42381 preservation of accession number NCIMB, herein also
Referred to as bacterial strain 830.The 16S rRNA sequence of 830 bacterial strains is provided in SEQ ID NO:3.Bacterial strain 830 was on March 12nd, 2015
By GT Biologics Co., Ltd (Life Sciences Innovation Building, Aberdeen, AB25 2ZS, Soviet Union
Glan) in International Depository Authority NCIMB (Ferguson Building, Aberdeen, AB21 9YA, Scotland) preservation be
" excrement Blaw spy Salmonella 830 " and specified deposit number are NCIMB 42381.GT Biologics Co., Ltd is then by it
Title is changed to 4D Pharma Research Co., Ltd. 
 Preferred Webster Blaw spy's Salmonella bacterial strain is with the bacterial strain of 42486 preservation of accession number NCIMB, herein also
Referred to as bacterial strain MRX008.The 16S rRNA sequence of MRX008 bacterial strain is provided in SEQ ID NO:4.Bacterial strain MRX008 was in 2015
November 16 by 4D Pharma Research Co., Ltd (Life Sciences Innovation Building,
Aberdeen, AB25 2ZS, Scotland) in International Depository Authority NCIMB (Ferguson Building, Aberdeen, AB21
9YA, Scotland) preservation is " Blaw spy Salmonella/Ruminococcus " and specified deposit number is NCIMB 42486. 
 It is also contemplated that the bacterium bacterial strain being closely related with the bacterial strain tested in embodiment is effective in increasing micropopulation multiplicity
Property and/or inducing microbial group's stability.In certain embodiments, have and hydrogen nutrition cloth for bacterium bacterial strain of the invention
The 16s rRNA sequence at least 97%, 98%, 99%, 99.5% or 99.9% identical 16s of the bacterium bacterial strain of labor spy Salmonella
RRNA sequence.Preferably, for bacterium bacterial strain of the invention have with SEQ ID NO:5 at least 97%, 98%, 99%,
99.5% or 99.9% identical 16s rRNA sequence.Preferably, there is 16s rRNA sequence for bacterium bacterial strain of the invention,
The sequence has the sequence of SEQ ID NO:5. 
 In certain embodiments, have and the bacterium bacterial strain of excrement Blaw spy Salmonella for bacterium bacterial strain of the invention
16s rRNA sequence at least 97%, 98%, 99%, 99.5% or 99.9% identical 16s rRNA sequence.Preferably, for this
The bacterium bacterial strain of invention has and SEQ ID NO:1 or SEQ ID NO:3 at least 97%, 98%, 99%, 99.5% or 99.9%
Identical 16s rRNA sequence.Preferably, sequence identity is for SEQ ID NO:3.Preferably, for bacterium of the invention
Bacterial strain has the 16s rRNA sequence indicated by SEQ ID NO:3.In certain embodiments, for bacterium bacterial strain of the invention
16s rRNA sequence at least 97%, 98%, 99%, 99.5% or 99.9% with the bacterium bacterial strain with Webster Blaw spy Salmonella
Identical 16s rRNA sequence.Preferably, have and SEQ ID NO:2 or SEQ ID NO:4 for bacterium bacterial strain of the invention
The identical 16s rRNA sequence of at least 97%, 98%, 99%, 99.5% or 99.9%.Preferably, sequence identity is to be directed to
SEQ ID NO:4.Preferably, there is the 16s rRNA sequence indicated by SEQ ID NO:4 for bacterium bacterial strain of the invention. 
 It is also contemplated that being with the bion of the bacterium of 10507/14294 preservation of accession number DSM or with accession number NCIMB
The bacterium bacterial strain of the bion of the bacterium of 42381 and NCIMB, 42486 preservation is effective in increasing micropopulation diversity and/or luring
Lead micropopulation stability.Bion is the bacterium being closely related with identical or closely similar physiology and biochemical characteristics
Strain. 
 It is the bion of the bacterium with accession number DSM 10507/14294, NCIMB 42381 or 42486 preservation of NCIMB
And being suitable for the invention bacterial strain can be by with accession number DSM 10507/14294, NCIMB 42381 or NCIMB
Other nucleotide sequences of the bacterium of 42486 preservations are sequenced to identify.For example, substantially full-length genome can be sequenced
And for biotype strains of the invention can have across its full-length genome at least 80% (for example, across at least 85%, 90%,
95% or 99%, or across its full-length genome) the sequence identity of at least 97%, 98%, 99%, 99.5% or 99.9%.Example
Such as, in some embodiments, biotype strains have at least 98% at least 98% sequence identity across its genome or
99% at least 99% sequence identity across its genome.Other suitable sequences of biotype strains may include for identification
Hsp60 or repetitive sequence, such as BOX, ERIC, (GTG) 5 Or REP or [28].Biotype strains can have and with accession number DSM
10507/14294, the corresponding sequence of the bacterium of 42486 preservation of NCIMB 42381 or NCIMB have at least 97%, 98%,
99%, the sequence of 99.5% or 99.9% sequence identity.In some embodiments, biotype strains have with accession number
The corresponding sequence of hydrogen nutrition Blaw spy's Salmonella bacterial strain of 10507/14294 preservation of DSM have at least 97%, 98%, 99%,
The sequence of 99.5% or 99.9% sequence identity, and include identical as SEQ ID NO:5 at least 99% (for example, at least
99.5% or at least 99.9% is identical) 16S rRNA sequence.In some embodiments, biotype strains have with log in
The corresponding sequence of hydrogen nutrition Blaw spy's Salmonella bacterial strain of number 10507/14294 preservation of DSM has at least 97%, 98%, 99%,
The sequence of 99.5% or 99.9% sequence identity, and the 16S rRNA sequence with SEQ ID NO:5. 
 It alternatively, is with the thin of accession number DSM 10507/14294, NCIMB 42381 or 42486 preservation of NCIMB
The bion of bacterium and be suitable for the invention bacterial strain can be by using 10507/14294 preserved material of accession number DSM, accession number
42381 preserved material of NCIMB or 42486 preserved material of accession number NCIMB and restriction fragment analysis and/or PCR analysis, for example, it is logical
It crosses and is cutd open using amplified fluorescence fragment length polymorphism (FAFLP) and (the rep)-PCR fingerprint analysis of repetition DNA element or protein
Analysis or part 16S or 23s rDNA sequencing are to identify.In preferred embodiments, such technology can be used to identify other hydrogen battalion
Support Blaw spy Salmonella, excrement Blaw spy Salmonella or Webster Blaw spy's Salmonella bacterial strain. 
 It in certain embodiments, is with accession number DSM 10507/14294, NCIMB 42381 or NCIMB 42486 guarantor
The bion of the bacterium of hiding and be suitable for the invention bacterial strain be when by amplification rDNA restriction analysis (ARDRA),
Such as it provides and when using Sau3AI restriction enzyme (for example, see the method and guidance of such as [29]) analysis with deposit number
The bacterial strain of DSM 10507/14294, NCIMB 42381 or the identical mode of bacterium of 42486 preservation of NCIMB.Alternatively,
Biotype strains be identified as with the thin of deposit number DSM 10507/14294, NCIMB 42381 or 42486 preservation of NCIMB
The bacterial strain of bacterium carbohydrate fermentation mode having the same. 
 Composition for use in the present invention and other Blaws spy Bordetella bacterial strain of method are (such as with accession number DSM
10507/14294, the bion of the bacterium of 42486 preservation of NCIMB 42381 or NCIMB) can be used any method appropriate or
Tactful (including measurement as described in the examples) identifies.For example, can be by cultivating bacterium and applying for bacterial strain of the invention
It is identified with to rat with being tested in abdominal distension measures.Specifically, and with accession number DSM 10507/14294, NCIMB
The bacterium of 42381 or NCIMB, 42486 preservation has the bacterium bacterium of similar growth pattern, metabolic type and/or surface antigen
Strain can be used for the present invention.Available bacterial strain has phase with DSM 10507/14294, NCIMB 42381 or 42486 bacterial strain of NCIMB
When micropopulation adjust activity.Specifically, biotype strains will cause with it is shown in embodiment effect it is comparable for
The effect of micropopulation, this can be identified by using the culture described in embodiment and application program. 
 Particularly preferred bacterial strain of the invention is the hydrogen nutrition Blaw spy Salmonella with 10507/14294 preservation of accession number DSM
Bacterial strain.This is the exemplary BH bacterial strain tested in embodiment, and is shown effective in increasing micropopulation diversity and/or luring
Lead micropopulation stability.Therefore, the present invention provides a kind of therapy for especially for disease as described herein and illness
Cell, such as with the separation cell of hydrogen nutrition Blaw spy's Salmonella bacterial strain of 10507/14294 preservation of accession number DSM or its derivative
Object. 
 It can with the derivative of accession number DSM 10507/14294, NCIMB 42381 or the bacterial strain of 42486 preservation of NCIMB
To be filial generation bacterial strain (offspring) from substance or from the bacterial strain (subclone) of substance culture.The derivative of bacterial strain of the invention can
It is for example modified under gene level in the case where not losing bioactivity.Specifically, derivative bacterial strain of the invention is
It is therapeutically effective.Derivative bacterial strain and original DSM 10507/14294, NCIMB 42381 or 42486 bacterial strain of NCIMB
Activity is adjusted with comparable micropopulation.Specifically, derivative bacterial strain will cause suitable with effect shown in embodiment
The effect for micropopulation, this can be identified by using the culture described in embodiment and application program.DSM
The derivative of 10507/14294 bacterial strain is usually the bion of 10507/14294 bacterial strain of DSM.42381 bacterial strain of NCIMB spreads out
Biology is usually the bion of 42381 bacterial strain of NCIMB.The derivative of 42486 bacterial strain of NCIMB is usually 42486 bacterium of NCIMB
The bion of strain. 
 To the reference with the cell of hydrogen nutrition Blaw spy's Salmonella bacterial strain of 10507/14294 preservation of accession number DSM cover with
With the bacterial strain safety having the same of 10507/14294 preservation of accession number DSM and any cell of therapeutic efficiency feature, and
And the present invention covers such cell.To the reference culvert with the cell of the excrement Blaw spy Salmonella of 42381 preservation of accession number NCIMB
Lid with the bacterial strain safety having the same of 42381 preservation of accession number NCIMB and any cell of therapeutic efficiency feature, and
And the present invention covers such cell.To the reference culvert with the cell of the Webster Blaw spy Salmonella of 42486 preservation of accession number NCIMB
Lid with the bacterial strain safety having the same of 42486 preservation of accession number NCIMB and any cell of therapeutic efficiency feature, and
And the present invention covers such cell. 
 In preferred embodiments, the bacterium bacterial strain in composition of the invention is great-hearted and can be partly
Or it is fully colonized in intestines. 
 Therapeutic use 
 In certain embodiments, composition of the invention is for increasing micropopulation diversity and/or inducing microbial
Group's stability.Reduced micropopulation diversity and/or reduced micropopulation stability and a variety of physiological maladies and illness phase
Association, and embodiment proves that composition of the invention can be effective in increasing micropopulation diversity and/or inducing microbial group
Stability.Therefore, the disease or illness that composition of the invention to be used treats or prevents preferably with relative to health by
The horizontal associated disease of the micropopulation diversity that the micropopulation diversity of examination person reduces or illness and/or micro- with reduction
The associated disease of biota stability or illness.Therefore, in some embodiments, the disease or illness can with relative to
The micropopulation that the micropopulation diversity of health volunteer reduces is multifarious horizontal associated and can also be micro- with reduction
Biota stability is associated. 
 In certain embodiments, composition of the invention is for treating or preventing disease or illness selected from the following:
It is IBS, IBD, obesity, diabetes B, one or more infectious diseases, one or more allergic diseases, one or more
Autoimmune disease and one or more metabolic disease/illnesss.It is contemplated that the treatment or prevention of other diseases and illness.At certain
In a little embodiments, composition of the invention is for treating or preventing IBS or IBD.In certain embodiments, group of the invention
Object is closed for treating or preventing IBS.In certain embodiments, composition of the invention is for treating or preventing IBD.Certain
In embodiment, composition of the invention is for treating or preventing one or more allergic diseases.In certain embodiments,
Composition of the invention is for treating or preventing obesity.In certain embodiments, composition of the invention for treat or
Prevent one or more infectious diseases.In certain embodiments, composition of the invention for treat or prevent it is a kind of or
Various autoimmune disease.In certain embodiments, composition of the invention is for treating or preventing one or more metabolism
Disease/illness.Preferably, the treatment or prevention, which are included in subject, increases micropopulation diversity and/or the micro- life of induction
Object group's stability. 
 In certain embodiments, one or more infectious diseases be selected from viral disease, bacteriosis or
Fungal disease.In certain embodiments, one or more allergic diseases are asthma.In certain embodiments,
One or more metabolic disease/illnesss are selected from diabetes such as diabetes B and obesity.In certain embodiments,
One or more autoimmune diseases are selected from multiple sclerosis and rheumatoid arthritis. 
 In certain embodiments, composition of the invention be used for by increase micropopulation micropopulation diversity come
Treat or prevent IBS, IBD, obesity, diabetes B, one or more infectious diseases, one or more allergic diseases,
One or more autoimmune diseases or one or more metabolic disease/illnesss.In certain embodiments, combination of the invention
Object is for treating or preventing IBS or IBD by inducing microbial group stability.In certain embodiments, group of the invention
Object is closed to be used to treat or prevent IBS by inducing microbial group stability 
 In preferred embodiments, the present invention provides a kind of composition of bacterium bacterial strain comprising Blaw spy Bordetella,
It is used to treat or prevent IBD, IBS, obesity, diabetes B, one or more infectious diseases, one or more allergic effects
Property disease, one or more autoimmune diseases or one or more metabolic disease/illnesss, wherein it is described treatment or prevention include
Increase micropopulation diversity and/or inducing microbial group's stability in subject. 
 In some embodiments, the present invention provides a kind of composition of bacterium bacterial strain comprising Blaw spy Bordetella,
For treating or preventing disease or illness selected from the following: IBS, IBD, obesity, diabetes B, one or more infectivities
Disease, one or more allergic diseases, one or more autoimmune diseases and one or more metabolic disease/illnesss.
In some embodiments, the present invention provides a kind of method for treating or preventing disease or illness selected from the following: IBS, IBD,
Obesity, diabetes B, one or more infectious diseases, one or more allergic diseases, one or more autoimmunities
Disease and one or more metabolic disease/illnesss comprising the composition of bacterium bacterial strain of the application comprising Blaw spy Bordetella. 
 In preferred embodiments, composition of the invention includes with the thin of 10507/14294 preservation of accession number DSM
Bacterium, and for increasing micropopulation diversity and/or inducing microbial group stability in subject with treat IBD, IBS,
Obesity, diabetes B, one or more infectious diseases, one or more allergic diseases, one or more autoimmunities
Disease or one or more metabolic disease/illnesss.In other preferred embodiment, composition of the invention includes to log in
The bacterium of number 10507/14294 preservation of DSM and for steady by increasing micropopulation diversity and/or inducing microbial group
It is qualitative to treat or prevent IBD, IBS, obesity, diabetes B, one or more infectious diseases, one or more allergic effects
Property disease, one or more autoimmune diseases or one or more metabolic disease/illnesss. 
 In some embodiments, the pathogenesis of the disease or illness influences intestines.In some embodiments, described
The pathogenesis of disease or illness does not influence intestines.In some embodiments, the pathogenesis of the disease or illness is confined to
Intestines.In some embodiments, the treatment or prevention occur at the position other than intestines.In some embodiments,
Described treat or prevent occurs in intestines and occurs also at the position other than intestines.In certain embodiments, the disease
Disease or illness are systematic. 
 In certain embodiments, the composition is used for for example when group's phase with health volunteer or health volunteer
Than when show or be expected to show the subject of reduced micropopulation diversity level.For example, in some embodiments,
The composition for treat in its micropopulation having less than 101 kinds of different bacteria cultures (for example, be less than 100,99,
98,97,96,95,93,90,85,80,75 or 70 kind of bacteria culture) and/or less than 195 kinds different bacterial strains (for example, being less than
193,190,187,185,183,180,175,170,165,160,150,140 kind of bacterium bacterial strain) subject.For example, one
In a little embodiments, the composition is for treating compared with health volunteer or compared with the group of health volunteer in its intestines
In road micropopulation having less than at least one bacterium category (for example, at least 2,3,4,5,6,7,8,9 or 10 kind of bacterium category) by
Examination person.In some embodiments, described to treat or prevent the following steps are included: being diagnosed as subject with the micro- life reduced
Object group diversity is horizontal and then if it find that there is reduced diversity level, then then with composition according to the present invention
Treat subject. 
 In certain embodiments, the composition is for showing or being expected to show reduced micropopulation stability
Subject.In some embodiments, the composition is used for for example when the group with health volunteer or health volunteer
Compared to when show or be expected to show the subject of the reduced stability of its micropopulation.In some embodiments, institute
It states and treats or prevents the following steps are included: subject is diagnosed as the reduced stability with its micropopulation and then such as
There is reduced stability in fruit discovery, then then treat subject with composition according to the present invention. 
 In certain embodiments, the subject is baby.In certain embodiments, the subject is children.
In certain embodiments, the subject is adult. 
 In certain embodiments, the subject is health volunteer.For example, in the composition for preventing disease
Or in some embodiments of illness, the subject is health volunteer, is optionally accredited as with Characteristics of Development being micro-
The subject of the risk of disease or illness that biota diversity reduces. 
 In certain embodiments, the subject had previously received, receiving or will receive antibiotic treatment.Cause
This, in some embodiments, the treatment or prevention be included in antibiotic treatment after, together with antibiotic treatment or anti-
Composition of the invention is applied before raw extract for treating.Composition of the invention and one or more antibiotic can be used for independent, same
When or sequence apply. 
 In some embodiments, composition of the invention is used to have increasing in its breathing relative to health volunteer
Increase the method for micropopulation diversity and/or inducing microbial group's stability in the subject of the hydrogen level added.In some realities
It applies in scheme, composition of the invention is horizontal for reducing the reduced diversity for showing or being expected to show its micropopulation
And/or the hydrogen in the breathing of the subject of reduced micropopulation stability is horizontal.The subject is preferably diagnosed as
With IBS, IBD, obesity, diabetes B, one or more infectious diseases, one or more allergic diseases, Yi Zhonghuo
The subject of various autoimmune disease and/or one or more metabolic disease/illnesss.It is controlled with what composition of the invention carried out
It is horizontal to treat the hydrogen for reducing and detecting in hydrogen breath test.Therefore, hydrogen breath test is preferably used to evaluate in hydrogen level.Hydrogen is exhaled
Inhaling test is well known in the art, and therefore technical staff will know how to implement this test.In some embodiment party
In case, subject is administered substrate of the lactulose as test. 
 Hydrogen breath test is also for monitoring increase micropopulation diversity and/or inducing microbial group stability and making
The validity of the treatment or prevention carried out with composition of the invention or the useful tool of possible validity.For example, with originally
The reduction of the hydrogen level detected in the breathing of subject after the composition treatment of invention can indicate that the treatment has and increase
Adding, stable, therapeutic or prophylactic action.Therefore, in some embodiments, the method and use of the invention be also
It is horizontal including hydrogen during and/or after being treated with composition of the invention in the breathing of monitoring subject, and therefore comment
The fixed validity or possible validity for increasing, stablizing, treating or preventing.For example, hydrogen level can be as needed at one or more
The monitoring of a (for example, 1,2,3,4 or be more than 4) time place, it may for example comprise before treatment, in treatment beginning, treating
Period monitors in treatment end and/or after the treatment.In some embodiments, will at the end of administration time section and/
Or the hydrogen level after administration time section (during composition is administered to subject) in the breathing of subject in administration time section
Level when beginning and/or before administration time section compares, and the level reduction instruction increase, stablize, treatment or
The validity of prevention or possible validity.For example, in the embodiment that administration time section is 16 days, it may be desirable to the 1st
It and the 16th day or for example on day 1, the 2nd day, the 15th day and the 16th day acquirement measured value.In some embodiments, it obtains
Multiple measured values and the average value of these measured values is obtained (for example, the 1st day and the 2nd day average value and the 15th day and the 16th
It average value).In some embodiments, at least 40ppm of the horizontal Cmax of hydrogen reduction instruction increase, stablize, treatment or
Prevention is effective or may be effective.In some embodiments, the hydrogen level in the breathing of subject is only for example being controlled
It is measured at the end for the treatment of or after treatment primary and described horizontal in predetermined horizontal lower or close to predetermined water
Flat discovery instruction increases, stablizes, treatment or prevention may be effective.Hydrogen breath test be standard test and therefore in advance
Determining level is well known in the art. 
 Treatment or prevention may refer to the mitigation of such as symptom severity or be the aggravation of the trigger of problem for subject
The reduction of frequency or range. 
 Standard technique (the qPCR technology such as used in embodiment) can be used to come from tested for bacterium in micropopulation
The excrement of person detects. 
 Administration mode 
 Preferably, composition of the invention be administered to gastrointestinal tract so as to allow bacterium bacterial strain of the invention be delivered to intestines and/
Or bacterium bacterial strain of the invention is partially or completely colonized in intestines.In general, composition oral of the invention is applied or they can be straight
Intestines intranasally or by oral cavity or epidural route are applied. 
 In certain embodiments, composition of the invention can be used as foam, apply as spray or gel. 
 In certain embodiments, composition of the invention can be used as suppository such as rectal suppository, such as (can in cupu oil
Can rouge), synthesize the shapes of stearic (for example, suppocire, witepsol), glycerol-gelatin, polyethylene glycol or soap glycerin compositions
Formula application. 
 In certain embodiments, composition of the invention passes through pipe (such as nose catheter, mouth stomach tube, stomach tube, jejunum stoma
Manage (J pipe), percutaneous endoscopic gastrostomy (PEG)) or port (such as provide the wall of the chest port in path for arriving stomach, jejunum or its
His suitable path port) it is administered to gastrointestinal tract. 
 Composition of the invention can apply that primary or they can be used as a part of therapeutic scheme and sequentially apply.?
In certain embodiments, composition of the invention is applied daily.Embodiment proves that daily application provides successfully delivering and clinic
Benefit. 
 In certain embodiments, composition of the invention is regularly applied, such as once a day, once every two days or often
All applied onces continue the extended period, such as continue at least one week, two weeks, January, two months, June or 1 year.Embodiment
Prove that the application of hydrogen nutrition Blaw spy Salmonella may not generate permanent intestines and colonize, so regularly applying the extended period can
More therapeutic and/or preventative benefits are provided. 
 In certain embodiments of the invention, treatment according to the present invention is with the intestinal microbiota to subject
Evaluation.If be not implemented bacterial strain of the invention delivering and/or partially or completely colonizing for bacterial strain of the invention and not see
Effect is observed, then repeats treatment, or if delivering and/or partially or completely colonizing successfully and observe effect, it can
Stop treatment. 
 In certain embodiments, composition of the invention can be administered to pregnant animal, such as the mammal such as mankind,
To prevent the horizontal and/or reduced micropopulation stability of reduced micropopulation diversity in her intrauterine and/or to go out
Occur with child after life. 
 Composition of the invention can be administered to subject, and the subject has been diagnosed with relative to health volunteer's
Reduced micropopulation diversity and/or reduced micropopulation stability, or with the reduction relative to health volunteer
Micropopulation diversity and/or the reduced associated disease of micropopulation stability or illness, or be accredited as having
There is the risk of the reduced micropopulation diversity and/or reduced micropopulation stability relative to health volunteer.It is described
Composition is alternatively arranged as preventive measure application to prevent to develop in health volunteer the reduction relative to health volunteer
Micropopulation diversity and/or reduced micropopulation stability. 
 Composition of the invention, which can be administered to, has been identified as the subject with abnormal intestinal microbiota.For example, institute
State subject can have it is reduction or being not present by Blaw spy Bordetella and specifically hydrogen nutrition Blaw spy Salmonella, excrement
What Blaw spy Salmonella or Webster Blaw spy Salmonella carried out colonizes. 
 Composition of the invention can be used as food product such as nutritional supplement and apply. 
 In general, composition of the invention, for treating the mankind, although they can be used for treating animal, including simple stomach lactation is moved
Object, such as poultry, pig, cat, dog, horse or rabbit.Composition of the invention can be used for enhancing the growth and performance of animal.If application
To animal, oral garage may be used. 
 Composition 
 In general, composition of the invention includes bacterium.In a preferred embodiment of the present invention, the composition is to freeze
Dry form is prepared.For example, composition of the invention may include particle or gelatine capsule, such as include bacterium bacterial strain of the invention
Hard gelatin capsule. 
 Preferably, composition of the invention includes the bacterium of freeze-drying.The freeze-drying of bacterium is the program well established, and phase
It closes guidance and is found in such as bibliography [30-32].Embodiment proves that freeze-drying compositions are particularly effective. 
 Alternatively, composition of the invention may include effective bacterial cultures living. 
 In some embodiments, the bacterium bacterial strain in composition of the invention is not inactivated, such as is not inactivated by heat.?
In some embodiments, the bacterium bacterial strain in composition of the invention is not killed, such as not heat-killed.In some embodiment party
In case, the bacterium bacterial strain in composition of the invention is not attenuated, such as is not attenuated by heat.For example, in some embodiments,
Bacterium bacterial strain in composition of the invention is not killed, inactivates and/or is attenuated.For example, in some embodiments, the present invention
Composition in bacterium bacterial strain be living.For example, in some embodiments, the bacterium bacterial strain in composition of the invention is
It is great-hearted.For example, in some embodiments, the bacterium bacterial strain in composition of the invention can partially or even wholly exist
Intestines colonize.For example, in some embodiments, the bacterium bacterial strain in composition of the invention is great-hearted and being capable of part
Ground is fully colonized in intestines. 
 In some embodiments, the composition includes bacterium bacterial strain living and the mixing of killed bacterium bacterial strain
Object. 
 In preferred embodiments, composition of the invention is packaged to allow bacterium bacterial strain being delivered to intestines.Encapsulation
Composition is protected not to be degraded, until for example, by (such as pressure, enzymatic activity can be changed by pH with chemical or physical stimulus
The physical disintegration of triggering) it ruptures to deliver in target position.Any packaging method appropriate can be used.Exemplary packaging technique packet
Include be embedded in porous matrix, adhere to or be adsorbed on solid carrier surface, by flocculation self aggregation or with crosslinking agent aggregation, with
And it is mechanical comprising after microporous barrier or microcapsules.Guidance about the encapsulation that can be used for preparing composition of the invention is found in
Such as bibliography [33] and [34]. 
 The composition palatable clothes are applied and can be in the form of tablet, capsule or powder.The product of encapsulation be it is preferred,
Because Blaw spy Salmonella is anaerobic bacteria.It may include other compositions (such as vitamin C) as oxygen scavenger and probiotics substrate
To improve delivering in vivo and/or partially or completely colonize and survive.Alternatively, probiotic composition of the invention can be used as food
Object or nutrition product (such as fermented dairy product based on milk or whey) are administered orally as drug products. 
 The composition can be formulated as probiotics. 
 Composition of the invention includes the bacterium bacterial strain of the invention of therapeutically effective amount.The bacterium bacterial strain foot of therapeutically effective amount
To apply beneficial effect to subject.The bacterium bacterial strain of therapeutically effective amount can be enough to generate delivering to the intestines of subject and/or
The intestines of subject partially or completely colonize. 
 Bacterium for example can be about 1x 10 for adult suitable daily dosage 3 To about 1x 10 11 A bacterium colony is formed
Unit (CFU)ÔºõFor example, about 1x 10 7 To about 1x 10 10 A CFUÔºõIn another example, about 1x 10 7 To about 1x 10 11 It is a
CFUÔºõIn another example, about 1x 10 8 To about 1x 10 10 A CFUÔºõIn another example, about 1x 10 8 To about 1x 10 11 
A CFUÔºõIn another example, about 1x 10 6 To about 1x 10 10 A CFU. 
 In certain embodiments, the dosage of bacterium is at least 10 9 A cell/day, such as at least 10 10 , at least about 10 11 
Or at least about 10 12 A cell/day. 
 In certain embodiments, the composition includes about 1 x 10 of the weight relative to composition 6 To about 1x
10 11 The bacterium bacterial strain of the amount of a CFU/gÔºõFor example, about 1x 10 8 To about 1x 10 10 A CFU/g.The dosage can be such as 1g,
3g, 5g and 10g. 
 In general, probiotics (composition such as of the invention) optionally at least one suitable Probiotic compounds group
It closes.Probiotic compounds are usually stodgy carbohydrate, such as oligosaccharides or polysaccharide or sugar alcohol, in upper digestive tract
In be not degraded or absorb.Known probiotics includes commercial product such as inulin and galacto-oligosaccharide. 
 In certain embodiments, probiotic composition of the invention includes about 1 to about 30 formed relative to total weight
The Probiotic compounds of the amount of weight % (for example, about 5 to 20 weight %).Carbohydrate can be selected from the group being made up of:
Fructo-oligosaccharide (or FOS), short-chain fructose-oligosaccharides, inulin, hydroxyl isomaltulose-oligosaccharides, pectin, wood oligose (or XOS), shell are poly-
Sugar-oligosaccharides (or COS), beta glucan, the gum arabic of modification and resistant starch, polydextrin, D-Tag, Acacia are fine
Dimension, carob, oat and citrus fruit fibres.On the one hand, probiotics be short-chain fructose-oligosaccharides (for simplicity, below
It is illustrated herein as FOS-c.c)ÔºõThe FOS-c.c. is stodgy carbohydrate, usually passes through the conversion of beet sugar
It obtains and includes the sucrose molecule that three glucose molecules are combined. 
 Composition of the invention may include pharmaceutically acceptable excipient or carrier.The example of such suitable excipient
It is found in bibliography [35].Acceptable carrier or diluent for therapeutic use are well known in pharmaceutical field, and
And the description for example in bibliography [36].The example of suitable carrier includes lactose, starch, glucose, methylcellulose, hard
Fatty acid magnesium, mannitol, sorbierite etc..The example of suitable diluent includes ethyl alcohol, glycerol and water.Pharmaceutical carrier, excipient
Or the selection of diluent is contemplated that expected administration method and standard pharmaceutical practice to select.Described pharmaceutical composition except carrier,
It may include any suitable adhesive, lubricant, suspending agent, coating agent, solubilizer except excipient or diluent.It is suitable viscous
The example of mixture includes starchÔºõGelatinÔºõNatural sugar, such as glucose, Lactis Anhydrous, the lactose of free-flowing, beta lactoseÔºõCorn
SweetenerÔºõNatural and rubber polymer, such as gum arabic, bassora gum or mosanom, carboxymethyl cellulose and polyethylene glycol.Properly
The example of lubricant include enuatrol, odium stearate, magnesium stearate, sodium benzoate, sodium acetate, sodium chloride etc..In the medicine
It can provide preservative, stabilizer, dyestuff and even flavoring agent in compositions.The example of preservative includes sodium benzoate, mountain
The ester of pears acid, cysteine and P-hydroxybenzoic acid.Antioxidant and suspending agent also can be used.Suitable carrier another
Example is sucrose.Another example of preservative is cysteine. 
 Composition of the invention can be formulated as food product.For example, food product can provide except therapeutic work of the invention
Nutritional benefits except, such as in the form of nutritional supplement.Similarly, food product can be prepared to enhance group of the invention
Close the taste of object or by more like come so that composition more inhales consumer with pharmaceutical composition with ordinary food
Gravitation.In certain embodiments, composition of the invention is configured to the product based on milk.Term " product based on milk " meaning
Refer to any liquid or the semisolid product based on milk or whey of modified fat content.Product based on milk can be
Such as milk, Goat Milk, ewe's milk, defatted milk, whole milk, by milk powder and whey recombination without any processing milk or add
Chemical product, such as yogurt, solidification milk, curdled milk, Yoghourt, acidification whole milk, butter cream and other sour milk products.Another is heavy
The group wanted includes milk drink such as whey beverage, cultured milk, condensed milk, baby or child's milkÔºõFlavored milk, ice creamÔºõFood containing milk
It is such as sugared. 
 In certain embodiments, composition of the invention includes single bacterium bacterial strain or strain and is free of any other
Bacterium bacterial strain or strain.Such composition can only include other bacterium bacterial strains or strain of amount pettiness or that biology is irrelevant.
Such composition can be culture or lyophilized products substantially free of other kinds of organism. 
 In certain embodiments, composition of the invention includes the bacterium bacterial strain of one or more Blaw spy Bordetellas,
Such as hydrogen nutrition Blaw spy Salmonella, and without containing any other bacterium category or its only include pettiness or biology it is irrelevant
Amount from another belong to bacterium.In certain embodiments, composition of the invention includes the list of Blaw spy Bordetella
One strain, such as hydrogen nutrition Blaw spy Salmonella, and without containing any other bacteria culture or its only include pettiness or raw
The bacterium from another strain of the irrelevant amount of object.In certain embodiments, composition of the invention includes that Blaw is special
The single bacterial strain of Bordetella, such as the single bacterial strain of hydrogen nutrition Blaw spy Salmonella, and do not contain any other bacterium bacterial strain bacterium
It plants or it only includes the bacterium from another bacterial strain or strain of amount pettiness or that biology is irrelevant. 
 In some embodiments, composition of the invention includes more than one bacterium bacterial strain or strain.For example, some
In embodiment, composition of the invention include it is more than one in same strain bacterial strain (for example, more than 1,2,3,4,5,
6,7,8,9,10,15,20,25,30,35,40 or 45 kind of bacterial strain), and optionally without from the thin of any other strain
Bacterium.In some embodiments, composition of the invention includes less than 50 kinds of bacterial strains in same strain (for example, being less than
45,40,35,30,25,20,15,12,10,9,8,7,6,5,4 or 3 kind of bacterial strain), and optionally without come from any other
The bacterium of strain.In some embodiments, composition of the invention include 1-40,1-30,1-20,1-19,1-18,1-15,
1-10„ÄÅ1-9„ÄÅ1-8„ÄÅ1-7„ÄÅ1-6„ÄÅ1-5„ÄÅ1-4„ÄÅ1-3„ÄÅ 1-2„ÄÅ2-50„ÄÅ2-40„ÄÅ2-30„ÄÅ2-20„ÄÅ2-15„ÄÅ2-10„ÄÅ2-5„ÄÅ6-30„ÄÅ
Bacterial strain of 6-15,16-25 or 31-50 kind in same strain, and optionally without from the thin of any other strain
Bacterium.In some embodiments, composition of the invention include it is more than one in same category strain (for example, more than 1,
2,3,4,5,6,7,8,9,10,12,15,17,20,23,25,30,35 or 40 kind of strain), and optionally without from any
Other bacteriums belonged to.In some embodiments, composition of the invention includes to be less than 50 kinds of strain (examples in same category
Such as, less than 50,45,40,35,30,25,20,15,12,10,8,7,6,5,4 or 3 kind of strain), and optionally without coming from
Any other bacterium belonged to.In some embodiments, composition of the invention includes 1-50,1-40,1-30,1-20,1-
15„ÄÅ1-10„ÄÅ1-9„ÄÅ1-8„ÄÅ1-7„ÄÅ1-6„ÄÅ1-5„ÄÅ1-4„ÄÅ1-3„ÄÅ1-2„ÄÅ2-50„ÄÅ 2-40„ÄÅ2-30„ÄÅ2-20„ÄÅ2-15„ÄÅ2-10„ÄÅ2-5„ÄÅ6-
30, strain of 6-15,16-25 or 31-50 kind in same category, and optionally without the bacterium belonged to from any other.
The present invention includes any combination of foregoing teachings. 
 In some embodiments, the composition includes microbial flora.For example, in some embodiments, it is described
Composition includes one of Blaw spy Bordetella bacterium bacterial strain such as hydrogen nutrition Blaw spy Salmonella bacterium bacterial strain as microbial flora
Part.For example, in some embodiments, Blaw spy Bordetella bacterium and it is one or more (for example, at least 2,3,4,5,10,
15 or 20 kind) from other belong to other bacterium bacterial strains combine exist, Blaw spy Bordetella bacterium can be with other described bacterium bacterium
Strain is symbiotically survived in intestines in vivo.For example, in some embodiments, the composition include with from not belonging to
Bacterium bacterial strain combination hydrogen nutrition Blaw spy Salmonella bacterium bacterial strain.In some embodiments, microbial flora include from
Two or more bacterium bacterial strains that the fecal specimens of the single creature body such as mankind obtain.In some embodiments, micro- life
Object flora finds to be not together in nature.For example, in some embodiments, microbial flora include from least two not
The bacterium bacterial strain that the fecal specimens of same organism obtain.In some embodiments, two different organisms are from same
Species, such as two different mankind.In some embodiments, two different organisms are the baby mankind and at everybody
Class.In some embodiments, two different organisms are the mankind and non-human mammal. 
 In some embodiments, composition of the invention additionally comprise have with accession number DSM 10507/14294
The identical safety of hydrogen nutrition Blaw spy's Salmonella bacterial strain of preservation and therapeutic efficacy but it is not with accession number DSM
The hydrogen nutrition Blaw spy Salmonella bacterial strain of 10507/14294 preservation or its be not hydrogen nutrition Blaw spy Salmonella or its be not Blaw
The bacterium bacterial strain of special Bordetella. 
 In some embodiments that composition of the invention includes more than one bacterium bacterial strain, strain or category, Ge Gexi
Bacteria strain, strain or belong to can be used for individually, be administered simultaneously or sequentially.For example, the composition may include described more than one thin
Bacteria strain, strain or belong in whole or the bacterium bacterial strain, strain or belong to can individually save and individually, simultaneously or it is suitable
Sequence application.In some embodiments, more than one bacterium bacterial strain, strain or category are individually saved but are mixed before the use
It is combined. 
 In some embodiments, it is obtained for bacterium bacterial strain of the invention from human faecal mass.In composition of the invention
In some embodiments comprising more than one bacterium bacterial strain, all bacterium bacterial strains are obtained from human faecal mass, or if are deposited
In other bacterium bacterial strains, they only exist with the amount of pettiness.In some embodiments, bacterium can obtain simultaneously from human faecal mass
And for being cultivated after composition of the invention. 
 In some embodiments, one or more Blaw spy Bordetella bacteriums be in composition of the invention only
One therapeutically active agent.In some embodiments, the bacterium bacterial strain in composition is unique in composition of the invention
Therapeutically active agent. 
 Market approval may be needed or may not be needed for composition used according to the invention. 
 In certain embodiments, pharmaceutical composition more than present invention offer, wherein the bacterium bacterial strain is freeze-drying.
In certain embodiments, pharmaceutical composition more than present invention offer, wherein the bacterium bacterial strain is spray-dried.At certain
In a little embodiments, the present invention provide more than pharmaceutical composition, wherein the bacterium bacterial strain is freeze-drying or is done by spraying
It is dry and wherein it is living.In certain embodiments, pharmaceutical composition more than present invention offer, wherein the bacterium bacterium
Strain be freeze-drying or carry out spray drying and wherein it is great-hearted.In certain embodiments, more than the present invention provides
Pharmaceutical composition, wherein the bacterium bacterial strain be freeze-drying or carry out spray drying and wherein it can be partially or completely
Ground is colonized in intestines.In certain embodiments, pharmaceutical composition more than present invention offer, wherein the bacterium bacterial strain is freeze-drying
Or carry out spray drying and wherein it is great-hearted and can partially or even wholly colonize in intestines. 
 In some cases, freeze-drying or the bacterium bacterial strain of spray drying be reconstructed before administration.In some cases
Under, the reconstruct is carried out by using diluent as described herein. 
 Composition of the invention may include pharmaceutically acceptable excipient, diluent or carrier. 
 In certain embodiments, the present invention provides a kind of pharmaceutical composition, it includes: bacterium bacterium as used in the present invention
StrainÔºõAnd pharmaceutically acceptable excipient, carrier or diluentÔºõWherein the bacterium bacterial strain exists with following amount: working as application
When to subject in need, it is sufficient to increase subject micropopulation diversity and/or inducing microbial group stability and/or
Treat disease associated with reduced micropopulation diversity and/or reduced micropopulation stability, micropopulation diversity
Disease, such as IBS, IBD, obesity, diabetes B, one or more infectious diseases, one or more allergic diseases,
One or more autoimmune diseases or one or more metabolic disease/illnesss. 
 In certain embodiments, the present invention provide more than pharmaceutical composition, wherein the amount of bacterium bacterial strain be relative to
About the 1 √ó 10 of the weight of composition 3 To about 1 √ó 10 11 A Colony Forming Unit/gram. 
 In certain embodiments, pharmaceutical composition more than present invention offer, wherein the composition is in 1g, 3g, 5g
Or it is applied under the dosage of 10g. 
 In certain embodiments, the present invention provide more than pharmaceutical composition, wherein the composition pass through selected from by
The method of group consisting of is applied: oral, rectum, subcutaneous, nasal cavity, oral cavity and sublingual. 
 In certain embodiments, pharmaceutical composition more than present invention offer, it includes selected from the group being made up of
Carrier: lactose, starch, glucose, methylcellulose, magnesium stearate, mannitol and sorbierite. 
 In certain embodiments, pharmaceutical composition more than present invention offer, it includes selected from the group being made up of
Diluent: ethyl alcohol, glycerol and water. 
 In certain embodiments, pharmaceutical composition more than present invention offer, it includes selected from the group being made up of
Excipient: starch, gelatin, glucose, Lactis Anhydrous, the lactose of free-flowing, beta lactose, corn sweetener, Arabic tree
Glue, bassora gum, mosanom, carboxymethyl cellulose, polyethylene glycol, enuatrol, odium stearate, magnesium stearate, sodium benzoate, acetic acid
Sodium and sodium chloride. 
 In certain embodiments, the present invention provide more than pharmaceutical composition, also include preservative, antioxidant and
At least one of stabilizer. 
 In certain embodiments, pharmaceutical composition more than present invention offer, it includes selected from the group being made up of
Preservative: the ester of sodium benzoate, sorbic acid and P-hydroxybenzoic acid. 
 In certain embodiments, pharmaceutical composition more than present invention offer, wherein the bacterium bacterial strain is freeze-drying. 
 In certain embodiments, pharmaceutical composition more than present invention offer, wherein when the composition is stored in about 4
DEG C or about 25 DEG C at sealing container in and container when being placed in the atmosphere with 50% relative humidity, such as with bacterium colony shape
Still retain after the period at least about below at least the 80% of the bacterium bacterial strain of unit measurement: January, March, June, 1 year,
1.5 years, 2 years, 2.5 years or 3 years. 
 In some embodiments, composition of the invention mentions in the sealing container comprising composition as described herein
For.In some embodiments, sealing container is pouch or bottle.In some embodiments, composition of the invention comprising
It is provided in the syringe of composition as described herein. 
 In some embodiments, composition of the invention is provided as pharmaceutical preparation.For example, the composition can provide for
Tablet or capsule.In some embodiments, the capsule is gelatine capsule (" gelcoat "). 
 In some embodiments, composition oral of the invention application.Oral administration can be related to swallow, so that compound
Into gastrointestinal tract, and/or it is related to oral cavity, tongue or sublingual administration, by the application, compound directly enters blood vessel from mouth. 
 Pharmaceutical preparation suitable for oral administration includes solid packing, Solid micro, semisolid and liquid (including multiphase
Or decentralized system), such as tabletÔºõContain the soft of more particles or nano particle, liquid (for example, aqueous solution), lotion or powder
Capsule or hard capsuleÔºõLozenge (including liquid filling)ÔºõMasticatoryÔºõGelÔºõFast dispersing dosage formÔºõFilmÔºõOvoidÔºõSprayÔºõWith
And oral cavity/mucoadhesive patches. 
 In some embodiments, the pharmaceutical preparation is Enteric formulations, that is, being suitable for will be of the invention by oral administration
Composition be delivered to the gastric tolerability preparations (for example, tolerance stomach pH) of intestines.Bacterium or another component when the composition
It is acid-sensitive, such as when being easy to degrade under acid conditions, Enteric formulations can be particularly useful. 
 In some embodiments, the Enteric formulations include enteric coatings.In some embodiments, the system
Agent is enteric coated dosage forms.For example, the preparation can be enteric coated tablet or enteric coated capsule etc..Enteric coatings can
To be conventional enteric coatings, for example, being used for the conventional coating of tablet, capsule of oral delivery etc..The preparation may include
Film coating, for example, the film layer of for example sour insoluble polymer of enteric polymer. 
 In some embodiments, Enteric formulations are substantially enteric solubilities, for example, gastric tolerability without intestines
Dissolubility coating.Therefore, in some embodiments, the preparation is the Enteric formulations for not including enteric coatings.Some
In embodiment, the preparation is the capsule made of thermal gelation material.In some embodiments, thermal gelation material is
Cellulosic material, such as methylcellulose, hydroxymethyl cellulose or hydroxypropyl methyl cellulose (HPMC).In some embodiments
In, the capsule includes the shell without containing any film forming polymer.In some embodiments, the capsule include shell simultaneously
And the shell includes hydroxypropyl methyl cellulose and does not include any film forming polymer (for example, with reference to [37]).Some
In embodiment, the preparation is the capsule of substantially enteric solubility (for example, from Capsugel company )„ÄÇ 
 In some embodiments, the preparation is soft capsule.Soft capsule is the softening due to being present in capsule housing
The agent such as addition of glycerol, sorbierite, maltitol and polyethylene glycol and can have certain elasticity and flexibility capsule.
Soft capsule can be generated for example based on gelatin or starch.Soft capsule based on gelatin can be commercially available from various suppliers.It is based on
The such as oral or rectal mode of method of administration, soft capsule can have various shape, they can be for example round, oval, ellipse
Round or torpedo.Soft capsule can such as pass through Scherer method, Accogel method or droplet or blowing process by conventional method
It generates. 
 Cultural method 
 The standard microorganism skill being such as described in detail in such as bibliography [38-40] can be used for bacterium bacterial strain of the invention
Art is cultivated. 
 Solid or fluid nutrient medium for culture can be YCFA agar or YCFA culture medium.YCFA culture medium may include
(every 100ml is about worth): junket peptone (1.0g), yeast extract (0.25g), NaHCO 3 (0.4g), cysteine (0.1g),
K 2 HPO 4 (0.045g)„ÄÅ KH 2 PO 4 (0.045g)„ÄÅNaCl(0.09g)„ÄÅ(NH 4 ) 2 SO 4 (0.09g)„ÄÅMgSO 4 ¬∑7H 2 O
(0.009g)„ÄÅCaCl 2 (0.009g), resazurin (0.1mg), hemin (1mg), biotin (1 Œº g), cobalamin (1 Œº g),
P-aminobenzoic acid (3 Œº g), folic acid (5 Œº g) and pyridoxamine (15 Œº g). 
 Bacterium bacterial strain for vaccine composition 
 Inventor has found that bacterium bacterial strain of the invention can be used to treat or prevent and micro- life relative to health volunteer
The micropopulation diversity that object group diversity (or micropopulation diversity of the group relative to health volunteer) reduces is horizontal
Associated disease or illness and/or micro- with the reduction compared to health volunteer (or compared to group of health volunteer)
The associated disease of biota stability or illness.This may be that bacterium bacterial strain of the invention has host immune system
Effect generate result.Therefore, when applying as vaccine composition, composition of the invention can also be used to prevent such disease
Disease or illness.In certain such embodiments, bacterium bacterial strain of the invention is great-hearted.In certain such embodiments
In, bacterium bacterial strain of the invention can be colonized partially or even wholly in intestines.In certain such embodiments, of the invention is thin
Bacteria strain is great-hearted and can partially or even wholly colonize in intestines.In other certain such embodiments, this hair
Bright bacterium bacterial strain can be killed, inactivates or be attenuated.In certain such embodiments, the composition may include vaccine assistant
Agent.In certain embodiments, the composition is used to such as be administered by subcutaneous injection by injection. 
 General provisions 
 Unless otherwise instructed, otherwise practice of the invention will be using the chemistry in the technology of this field, biochemistry, molecule
The conventional method of biology, immunology and pharmacy.Such technology is fully explained in the literature.See, e.g. bibliography
[41] and [42-48] etc.. 
 Term "comprising" cover " comprising " and " by ... form ", such as the composition of "comprising" X can be exclusively by X group
At or may include other things, such as X+Y. 
 Term " about " relevant to numerical value x is optional and is average value, such as x ¬± 10%. 
 Word " substantially " is not excluded for " fully ", such as the composition of substantially free Y can be entirely free of Y.It is needing
In the case where wanting, word " substantially " can be omitted from definition of the invention. 
 The reference of Percent sequence identity between two nucleotide sequences means when aligned, to compare two sequences
The percentage of nucleotide is identical.Software known in the art can be used in this alignment and Percent homology or sequence identity
Program, such as those are determined described in the 7.7.18 chapters and sections of bibliography [49].Preferred compare passes through Smith-
Waterman homology search algorithm is spaced open point penalty (gap open penalty) and is using having for affine IV interval
12, it is 62 to determine that interval extension point penalty (gap extension penalty), which is 2, BLOSUM matrix,.Smith-Waterman
Homology search algorithm discloses in bibliography [50]. 
 Unless explicitly stated otherwise, otherwise the technique including multiple steps or method can start in method or at the end of include another
Outer step may include other inserting step.In addition, in appropriate circumstances, step can be combined, be omitted or can replace
The sequence in generation executes. 
 Various embodiments of the present invention are described herein.It should be understood that the feature specified in each embodiment can
Specified feature is combined to provide other embodiments with other.Specifically, it is suitable, typical for highlighting herein
Or preferred embodiment can be combined with each other (except when they are mutually exclusive). 
 Implement mode of the invention 
 
 
 The variation of embodiment 1- patients suffering microbial group after hydrogen nutrition Blaw spy Salmonella is handled 
 
 It summarizes 
 
 Diversity and stability of the test hydrogen nutrition Blaw spy Salmonella for patients suffering microbial group in health and IBS patient
Effect. 
 
 Method 
 
 
 Researching and designing 
 
 Implement Phase I clinical trial, wherein by hydrogen nutrition Blaw spy Salmonella (" Blautix ", simultaneously with accession number DSM 10507
And also with the bacterial strain of 14294 preservation of accession number DSM) it is administered to human patients or healthy human patient with IBS.It is being administered
Blautix is applied to patient during (the 1-16 days) period, wherein scavenging period Duan Wei 19-23 days.: baseline, processing
The 1st day (D1) beforeÔºõProcessing terminate, and the 16th day (D-16)ÔºõAnd research, when terminating (EOS), 2-4 week after the treatment (clearly
Wash), faecal samples are acquired from the IBS and health volunteer handled with placebo or Blautix. 
 
 The sequencing of 16S amplicon 
 
 : baseline, the 1st day (D1) before processingÔºõProcessing terminate, and the 16th day (D-16)ÔºõAnd research is when terminating (EOS),
Its 2-4 weeks after the treatment (cleaning), it then follows the specification of manufacturer using Qiagen DNeasy blood and Tissue kit from
Microbial DNA is extracted come the 0.2g freezing faecal samples of the IBS of use by oneself placebo or Blautix processing and health volunteer. 
 It is prepared using the 16S sequencing library developed by Illumina company (Santiago, California, the U.S.)
The preparation and sequencing of Nextera scheme implementation 16S rRNA gene amplicon.Use the V3/ of PCR and targeting 16S rRNA gene
Each DNA of the primer amplification 50ng of the variable region V4 drains extract.Purified product and the adapter PCR taken turns by second
It is attached forward and reverse bar code.Resulting PCR product is purified, is quantitative, and then by every kind of expansion of equimolar amounts
Increase in subset, is sent to commercial supplier GATC Co., Ltd later in MiSeq (2 √ó 250bp chemistry) or HiSeq
It is sequenced on (2x 300bp chemistry) platform. 
 
 Data analyze (after sequencing) 
 
 Merge finishing original sequence data using flash method.This filters out low quality reading.Use USEARCH pipeline
Method (8.1.1861_i86_linux64 version) identification is single to be now mutated and walks them from OTU (activity classification unit) generation
It is rapid to hide.Using UPARSE algorithm come by Sequence clustering into OTU.With (the downloading: 2016 of Chimeraslayer reference database
On September 9), the chimeric sequences generated in amplification step are removed using UCHIME chimera removal algorithm.Then it uses
All readings (including single existing mutation) is mapped in remaining OUT sequence by USEARCH overall comparison algorithm.Then using inside
Script is by sequence of packets into the OUT such as to be classified by USEARCH overall comparison algorithm.By individual sequence of packets into OUT with
Provide microorganism group composition information (abundance and diversity). 
 
 High level of data analysis 
 
 Bray-Curtis distinctiveness ratio square is generated for the pairing of each sample using the Vegan picture library 3.3.1 in R language
Battle array.With Bray-Curtis dissimilarity matrix, using principal coordinate analysis by data set visualization. 
 Thermal map visual effect is generated using internal thermal map R function, wherein connecting based on Bray-Curtis distinctiveness ratio and ward
Tap into row hierarchical cluster. 
 Shannon diversity index and Simpson's diversity index are generated using in the library phyloseq of R language. 
 Identify that for selected comparison be significant classified variable using DESeq2 method. 
 Displacement MANOVA is executed on dissimilarity matrix using the Adonis function in R language. 
 
 As a result 
 
 Concentrate two groups from all time points sample (71 IBS patients and 67 normal healthy controls, including
Both Blautix processing group and placebo).Analysis is executed using the distance measure generated on full microorganism group data set.
The micropopulation of Fig. 1 report IBS subject and the micropopulation of health volunteer are dramatically different. 
 Use the taxon (OTU) of prediction, the numerical value of Shannon diversity index and Simpson's diversity index observed
Implement diversity analysis.Two processing groups are multifarious when being shown in the 16th day time point to increase that (this is for the OTU that observes
It is significant) and show the trend (raw P values: < 0.1) (Fig. 2) of Simpson.This diversity increase is not with placebo treatment
Patient in the case where observe.Observed in untreated IBS placebo research at the end of with the 1st day between micro- life
Object group is multifarious to be dramatically increased. 
 Fig. 3 reports that Blautix processing increases the micropopulation network connectivity of the relevant taxon of certain health.In health
In patient, observe that internal the substantive of microorganism connection increases (after Blautix processing) from the 1st day to the 16th day, this table
The increase (Fig. 3 A) of bright cooperation and micropopulation structure.Connectivity is related to diversity and stability.After scavenging period section,
Network structure returns to what is observed on day 1 similar network.Therefore, Blautix processing increases mutual in healthy patients
Lian Xing, but the event resolves after the washing.In IBS patient, network is on day 1 about connectivity between the 16th day
It keeps similar, but observes that connectivity increases at the end of the study, to show clear in the IBS patient of Blautix processing
Micropopulation structure increases (Fig. 3 B) after washing the period.Therefore, compared with healthy patients, Blautix connects microorganism group
Acting in IBS patient for connecing property postpones. 
 Unstability/variation of micropopulation distribution is by the Bray Curtis between the time point of same target apart from table
Show.Bray-Curtis shows the distinctiveness ratio being limited between 0-1 between strain abundance distribution, and (0=is identicalÔºõ1=does not share any
Strain).With Blautix processing IBS patient during processing (Fig. 4 A) and processing after (Fig. 4 B to Fig. 4 C) reduction micropopulation
The magnitude of variation.This display Blautix increases the micropopulation stability in IBS patient and the variation continues to intervention
Afterwards.When IBS patient is administered placebo, this increased stability (Fig. 4 A to Fig. 4 C) is not observed. 
 Micropopulation of the IBS patient that Fig. 5 report was handled at the 16th day with Blautix compared with the 1st day in the case where belonging to horizontal
Diversity, which exists, to be dramatically increased.Using be applied to category level Shannon diversity index implement diversity analysis (original p value:
0.04, the 1st day relative to the 16th day). 
 Fig. 6 A and Fig. 6 B are shown in the variation of health and alternative network in IBS patient after Blautix processing.In health
In individual, alternative network became more dense at the 16th day and interconnects, this shows to compete and inhibits to increase.However, this is acted on
It is lost at the end of research, because network structure returns to initial time point (Fig. 6 A) during scavenging period section.In IBS patient
In, Blautix effect internuncial for alternative is to increase network diameter during processing period and scavenging period section.This
It is opposite to become more dense effect with the network seen in healthy individuals.During the wash phase of IBS patient, observe previously
The multiple independent interactions that do not see.Multiple independent interactions indicate in a manner of the remainder independently of network
The taxon pair of interaction, that is, they do not have any interaction of the remainder for network. 
 After Blautix processing, taxon relevant for certain health exists to be increased the visualization display of micropopulation
The network connectivity (Fig. 7) added.The relevant taxon of health includes fusobacterium cluster IV, Bifidobacterium and melaninogenicus
Belong to.Bactoscilla is also likely to be the relevant category of health.These relevant taxons of health involve the response to processing. 
 
 
 Protective effect in the model of embodiment 2- neurodevelopmental disorders 
 
 BTBR mouse model 
 
 BTBR mouse model uses the gene modification mouse of inbreeding, shows steady autism sample phenotype.In this product
Report that Social behaviors lack, repeat behavior increase and anxiety corelation behaviour increase [51] in kind.Due to this steady behavior table
Type, BTBR are the ideal animals models for evaluating new therapeutic agent for the therapeutic efficiency of autism corelation behaviour.By having
The biopharmaceuticals of effect, which mitigate such symptom, may further indicate that biopharmaceuticals are treating other psychiatry and neurology diseases
In effect. 
 
 Mouse 
 
 Male BTBR is fed indoors.With 12 hours dark cycles (opening light when from 7:00-19:00) by animal stable breeding
In the controlled room of temperature and humidity.According to Europe instruction 2010/63/EEC, 2012 No. S.I. 543 requirement and
Ratify through Cork university animal experimental Ethics Committee to implement all experiments. 
 
 Bacterial strain 
 
 With accession number DSM 10507 and also with the hydrogen nutrition Blaw spy Salmonella of 14294 preservation of accession number DSM. 
 Biopharmaceuticals are provided with glycerol stocks.Effective biopharmaceuticals are grown in the equipment in anaerobic condition. 
 
 Effective biopharmaceuticals application 
 
 When mouse 8 weeks big, implement the administration carried out with hydrogen nutrition Blaw spy Salmonella.Once a day by oral garage
These mouse are handled, it is for 3 weeks. 
 
 Administration time table 
 
 Medium for oral administration is PBS.It is administered orally and is carried out by oral garage daily. 
 
 Feces collection 
 
 Fresh excreta sample is acquired from individual mouse before and after applying hydrogen nutrition Blaw spy Salmonella.By at least 20mg
Fresh excreta be placed in micro-centrifuge tube, be put on ice for and then saved at -80 DEG C immediately. 
 
 As a result 
 
 Effect of the Blautix processing for micropopulation between time point (D14, D32) is shown in FIG. 8.It is handling
Observed between (D32) search time point after (D14) and processing before micropopulation distribution significant time change (p value=
0.001)„ÄÇ 
 It is generated using the variance analysis of DESeq2 and is handled between D14 and D32 autism search time point for Blautix
25 significant (adjustment p value < 0.05) different abundant taxon.Taxon is listed in the following table 1. 
 
 
 
 
 
 
 Dramatically different abundant taxon in 1. autism research of table between D14 and D32 time point.Positive multiple variation
It is construed to increase at D32 when compared with D14. 
 
 It summarizes 
 
 Into the lonely disease mouse model of animal application Blautix, the significant changes of its microorganism group are observed, including
The substantive net increase of Phylogenetic diversity of bacteria. 
 
 
 Effect in the model of embodiment 3- cerebral ischemia 
 
 It summarizes 
 
 The protective effect of hydrogen nutrition Blaw spy Salmonella is tested in the mouse model of cerebral ischemia.For this purpose, three groups of test
5-17 mouse.It under study for action only include the normal animal of behavior.First administration time is the -14th day.One group is from first
Administration time receives the bacterium of freeze-drying daily, until stopping.Control group receives medium or freeze-drying buffer
(lyobuffer)„ÄÇ 
 On day 1, all mouse are anaesthetized.It is total to expose right side and left side that midline incision is generated in the veutro of neck
Arteria carotis.Then continue to fill again to generate cerebral ischemia-for 15 minutes by two sides general neck artery obstruction (BCCAO) using blood vessel clip
Infuse I/R model.At the end of each obstruction, fixture is removed. 
 
 Bacterial strain 
 
 With accession number DSM 10507 and also with the hydrogen nutrition Blaw spy Salmonella of 14294 preservation of accession number DSM. 
 
 Administration time table 
 
 
 
 
 
 Researching and designing 
 
 - 14th day to the 14th day: PBS control (freeze-drying buffer), the powder control (medium) being freeze-dried freezed
The daily dosage of dry bacterium (Blautix). 
 1st day: the global cerebral ischemia-reperfusion I/R model generated by operation. 
 14th day: stopping the half mouse in each group. 
 14th day to the 28th day: for the PBS control (freeze-drying buffer) of mouse remaining in each group, the powder of freeze-drying
Foot couple is according to (medium) or the daily dosage of the bacterium (Blautix) of freeze-drying. 
 28th day: stopping remaining mouse. 
 The acquisition excrement particle at three time points: the -14th day, the 14th day and the 28th day.In gnotobasis
Implement in (integral asepsis=cleaned between animal) to obtain every time, wherein every mouse is taken out from cage and independent
It is placed into new sterile board to be harvested for individual particles.It is minimum to reach every mouse to acquire particle as much as possible
The material of 80mg and preferably 100mg. 
 
 As a result 
 
 In D-14, Blautix processing, medium and freeze-drying is not detected in (p value=0.177) before applying Blautix
The significant difference of micropopulation distribution between buffer group (referring to Fig. 9 A).However, at the 14th day in different processing groups
Between observe micropopulation distribution significant difference (referring to Fig. 9 B), wherein observing 0.011 p value.Inventor also evaluates
The time change of the micropopulation of Blautix processing group and significant difference (referring to Fig. 9 C) is found, wherein observing 0.002
P value. 
 It is generated between the time point in apoplexy research using the variance analysis of DESeq2 for medium, freeze-drying buffer
The different abundant taxon with significant (adjustment p value < 0.05) of Blautix processing, as shown in table 2, to prove by Blautix
The long-term influence for Phylogenetic diversity of bacteria generated.The taxon of Blautix processing is listed in table 3, table 4 and table 5. 
 
 
 
 
 
   
 D-14->D14 
 D14->D28 
 D-14->D28 
 
 
 Medium 
 4 
 0 
 2 
 
 
 Buffer is lyophilized 
 17 
 2 
 0 
 
 
 Blautix 
 7 
 14 
 12  
 
 
 
 
 
 Dramatically different abundant taxon in 2. apoplexy research of table between time point. 
 
 
 
 For dramatically different abundant point between D-14 the and D14 time point of Blautix processing in 3. apoplexy research of table
Monoid.Positive multiple change interpretation is to increase at D14 when compared with D-14. 
 
 
 
 For the dramatically different abundant classification between D14 the and D28 time point of Blautix processing in 4. apoplexy research of table
Group.Positive multiple change interpretation is to increase at D28 when compared with D14. 
 
 
 
 
 
 
 For dramatically different abundant point between D-14 the and D28 time point of Blautix processing in 5. apoplexy research of table
Monoid.Positive multiple change interpretation is to increase at D28 when compared with D-14. 
 Using DESeq2 variance analysis generate apoplexy search time point for Blautix processing relative to medium with
And the abundant taxon that Blautix processing is different relative to significant (adjustment p value < 0.05) of freeze-drying buffer, as shown in table 6.
Taxon is listed in table 7, table 8 and table 9. 
 
 
 
 For the dramatically different abundant taxon of Blautix processing in 6. apoplexy research of table. 
 
 
 
 The dramatically different abundant taxon relative to medium is handled for Blautix in 7. apoplexy research of table. 
 
 
 
 It is enriched for Blautix processing relative to the dramatically different of freeze-drying buffer in 8. apoplexy research of table in D-14
Taxon 
 
 
 
 It is enriched for Blautix processing relative to the dramatically different of freeze-drying buffer in 9. apoplexy research of table in D14
Taxon 
 
 It summarizes 
 
 When compared with buffer or intermedium control is lyophilized, Blautix is in apoplexy mouse model in entire research
Between realize that micropopulation is multifarious in section and dramatically increase. 
 
 
 Protective effect in the model of embodiment 4- neuritic symptom 
 Experimental autoimmune encephalomyelitis (EAE) is to reflect that human diseases MS's is permitted the small of various CNS inflammation
Mouse model, and EAE is the most-often used experimental model for mankind MS.EAE is also more typically used as CNS specificity itself
Immune disorders [52] and the model for being used for other specific symptom (including Acute Disseminated encephalomyelitis).EAE use is with marrow phosphorus
The booster immunization that lipopeptid and adjuvant carry out induce with cause be closely corresponding to CNS many autoimmunities and inflammatory conditions and
The immune and inflammatory response for the mechanism that especially MS is based on.Show many therapies of effect also in human patients in EAE
Effect [52] are shown in MS treatment.Most of all, EAE reproduces the main feature of MS, including inflammation, demyelinate, axonal loss
And gliosis.The influence of demyelinate is limited primarily to spinal cord in EAE, the change with seldom brain stem and cerebellum.
In EAE, CD4+T cell is the cell colony present in CNS in the highest flight. 
 
 Method 
 
 By hydrogen nutrition Blaw spy Salmonella (" Blautix ", with accession number DSM 10507 and also with accession number DSM 14294
The bacterial strain of preservation) it is used as the powder of freeze-drying and reconstructs as needed. 
 Use 12 Adult female C57BL/6J mouse. 
 The 0th day and the 7th day, MOG35-55 is contained to animal application by subcutaneous injection under gas (isoflurane) anesthesia
Lotion and supplement have the complete Freund's adjuvant (CFA) of mycobacterium tuberculosis H37Ra.At the 0th day, two skins are executed in flank
Lower injectionÔºõEach one in each lower part quadrant at back.At the 7th day, two subcutaneous injections are executed in flankÔºõAt back
Each one in each upper quadrant. 
 The 0th day and the 2nd day, one hundred days for animal being applied in by intraperitoneal injection in phosphate buffered saline (PBS) (PBS)
Cough toxin (PTx).At the 0th day, PTx application is executed after MOG application. 
 The processing carried out with Blautix or control was applied from the -14th day according to following timetable: 
 0th day: MOG/CFA, once, SC 
 0th day: PTx, once, IP 
 2nd day, PTx, once, IP 
 7th day: MOG/CFA, once, SC 
 The application processing in 15 minutes of its preparation.In 2x 10 8 Dosage under apply BlautixÔºõ100 Œº l/ mouse. 
 From the 0th day up to experiment terminate, the clinical manifestation for EAE daily scores to animal, including tail and/or
The paresis and paralysis of four limbs. 
 At the -14th day, the -1st day and the 34th day, fecal pellets are acquired from every animal, are freezed immediately and at -80 DEG C
Lower preservation. 
 
 As a result 
 
 The Blautix between time point (D-14, D-1, D34) that MS model is shown in FIG. 10 is handled for microorganism
The effect of group.The significant time change (p value=0.001) of micropopulation distribution is observed for search time point. 
 Using DESeq2 variance analysis generate search time point between for Blautix processing it is significant (adjustment p value <
0.05) different abundant taxon, as shown in table 10.Taxon is listed in table 11, table 12 and table 13. 
 
 
 
 
 
   
 D-14->D-1 
 D-1->D34 
 D-14->D34 
 
 
 MS(Blautix) 
 42 
 30 
 58  
 
 
 
 
 
 Dramatically different abundant taxon in table 10.MS research between time point. 
 
 
 
 
 
 
 Dramatically different abundant taxon in table 11.MS research between D-14 and D-1 time point.Positive multiple variation solution
It is interpreted as increasing at D-1 when compared with D-14. 
 
 
 
 
 
 
 Dramatically different abundant taxon in table 12.MS research between D-1 and D34 time point.Positive multiple variation solution
It is interpreted as increasing at D34 when compared with D-1. 
 
 
 
 
 
 
 
 
 
 Dramatically different abundant taxon in table 13.MS research between D-14 and D34 time point.Positive multiple variation solution
It is interpreted as increasing at D34 when compared with D-14. 
 
 It summarizes 
 
 Blautix realizes that micropopulation is multifarious and dramatically increases and locating in the animal model of multiple sclerosis
Cause significant time change during reason. 
 Only the scope of the claims is fallen in and it will be understood that can make in the above description present invention by way of example
Interior other change. 
 Sequence 
 SEQ ID NO:1 (excrement Blaw spy's Salmonella bacterial strain GAM6-1 16S ribosomal RNA gene, partial sequence-
HM626177) 
 
 
 
 SEQ ID NO:2 (14507 16S rRNA gene of Webster Blaw spy's Salmonella bacterial strain WAL, partial sequence-
EF036467) 
 
 
 
 SEQ ID NO:3 (the shared 16S rRNA sequence of excrement Blaw spy Salmonella bacterial strain 830) 
 TTTKGTCTGGCTCAGGATGAACGCTGGCGGCGTGCTTAACACATGCAAGTCGAGCGAAGCGCTTACGA
CAGAACCTT CGGGGGAAGATGTAAGGGACTGAGCGGCGGACGGGTGAGTAACGCGTGGGTAACCTGCCTCATACA
GGGGGATAACA GTTGGAAACGGCTGCTAATACCGCATAAGCGCACAGTATCGCATGATACAGTGTGAAAAACTCC
GGTGGTATGAGAT GGACCCGCGTCTGATTAGCTAGTTGGAGGGGTAACGGCCCACCAAGGCGACGATCAGTAGCC
GGCCTGAGAGGGTGA ACGGCCACATTGGGACTGAGACACGGCCCAGACTCCTACGGGAGGCAGCAGTGGGGAATA
TTGCACAATGGGGGAAA CCCTGATGCAGCGACGCCGCGTGAAGGAAGAAGTATCTCGGTATGTAAACTTCTATCA
GCAGGGAAGAAAATGACGG TACCTGACTAAGAAGCCCCGGCTAACTACGTGCCAGCAGCCGCGGTAATACGTAGG
GGGCAAGCGTTATCCGGATTT ACTGGGTGTAAAGGGAGCGTAGACGGAAGAGCAAGTCTGATGTGAAAGGCTGGG
GCTTAACCCCAGGACTGCATTGG AAACTGTTTTTCTTGAGTGCCGGAGAGGTAAGCGGAATTCCTAGTGTAGCGG
TGAAATGCGTAGATATTAGGAGGAA CACCAGTGGCGAAGGCGGCTTACTGGACGGTAACTGACGTTGAGGCTCGA
AAGCGTGGGGAGCAAACAGGATTAGAT ACCCTGGTAGTCCACGCCGTAAACGATGAATACTAGGTGTTGGGGAGC
AAAGCTCTTCGGTGCCGCAGCAAACGCAA TAAGTATTCCACCTGGGGAGTACGTTCGCAAGAATGAAACTCAAAG
GAATTGACGGGGACCCGCACAAGCGGTGGAG CATGTGGTTTATTCGAAGCAACGCGAAGAACCTTACCAAGTCTT
GACATCGATCTGACCGGTTCGTAATGGAACCTT TCCTTCGGGACAGAGAAGACAGGTGGTGCATGGTTGTCGTCA
GCTCGTGTCGTGAGATGTTGGGTTAAGTCCCGCAA CGAGCGCAACCCCTATCGTCAGTAGCCAGCAGGTAAAGCT
GGGCACTCTGAGGAGACTGCCAGGGATAACCTGGAGG AAGGCGGGGACGACGTCAAATCATCATGCCCCTTATGA
TTTGGGCTACACACGTGCTACAATGGCGTAAACAAAGGG AAGCGAGCCCGCGAGGGGGAGCAAATCCCAAAAATA
ACGTCCCAGTTCGGACTGCAGTCTGCAACTCGACTGCACGA AGCTGGAATCGCTAGTAATCGCGAATCAGAATGT
CGCGGTGAATACGTTCCCGGGTCTTGTACACACCGCCCGTCAC ACCATGGGAGTCAGTAACGCCCGAAGTCAGTG
ACCCAACCTTAGGGAGGGAGCTGCCGAAGGCGGGATTGATAACTG GGGTGAAGTCTAGGGGGT 
 SEQ ID NO:4 (the shared 16S rRNA sequence of Webster Blaw spy's Salmonella bacterial strain MRX008) 
 TTCATTGAGACTTCGGTGGATTTAGATTCTATTTCTAGTGGCGGACGGGTGAGTAACGCGTGGGTAAC
CTGCCTTAT ACAGGGGGATAACAGTCAGAAATGGCTGCTAATACCGCATAAGCGCACAGAGCTGCATGGCTCAGT
GTGAAAAACTC CGGTGGTATAAGATGGACCCGCGTTGGATTAGCTTGTTGGTGGGGTAACGGCCCACCAAGGCGA
CGATCCATAGCCG GCCTGAGAGGGTGAACGGCCACATTGGGACTGAGACACGGCCCAGACTCCTACGGGAGGCAG
CAGTGGGGAATATTG CACAATGGGGGAAACCCTGATGCAGCGACGCCGCGTGAAGGAAGAAGTATCTCGGTATGT
AAACTTCTATCAGCAGG GAAGATAGTGACGGTACCTGACTAAGAAGCCCCGGCTAACTACGTGCCAGCAGCCGCG
GTAATACGTAGGGGGCAAG CGTTATCCGGATTTACTGGGTGTAAAGGGAGCGTAGACGGTGTGGCAAGTCTGATG
TGAAAGGCATGGGCTCAACCT GTGGACTGCATTGGAAACTGTCATACTTGAGTGCCGGAGGGGTAAGCGGAATTC
CTAGTGTAGCGGTGAAATGCGTA GATATTAGGAGGAACACCAGTGGCGAAGGCGGCTTACTGGACGGTAACTGAC
GTTGAGGCTCGAAAGCGTGGGGAGC AAACAGGATTAGATACCCTGGTAGTCCACGCCGTAAACGATGAATACTAG
GTGTCNGGGGAGCATGGCTCTTCGGTG CCGTCGCAAACGCAGTAAGTATTCCACCTGGGGAGTACGTTCGCAAGA
ATGAAACTCAAAGGAATTGACGGGGACCC GCACAAGCGGTGGAGCATGTGGTTTAATTCGAAGCAACGCGAAGAA
CCTTACCAAGTCTTGACATCCGCCTGACCGA TCCTTAACCGGATCTTTCCTTCGGGACAGGCGAGACAGGTGGTG
CATGGTTGTCGTCAGCTCGTGTCGTGAGATGTT GGGTTAAGTCCCGCAACGAGCGCAACCCCTATCCTCAGTAGC
CAGCATTTAAGGTGGGCACTCTGGGGAGACTGCCA GGGATAACCTGGAGGAAGGCGGGGATGACGTCAAATCATC
ATGCCCCTTATGATTTGGGCTACACACGTGCTACAAT GGCGTAAACAAAGGGAAGCGAGATCGTGAGATGGAGCA
AATCCCAAAAATAACGTCCCAGTTCGGACTGTAGTCTGC AACCCGACTACACGAAGCTGGAATCGCTAGTAATCG
CGGATCAGAATGCCGCGGTGAATACGTTCCCGGGTCTTGTA CACACCGCCCGTCACACCATGGGAGTCAGTAACG
CCCGAAGTCAGTGACCTAACTGCAAAGAAGGAGCTGCCGAA 
 SEQ ID NO:5 (hydrogen nutrition Blaw spy's Salmonella bacterial strain S5a36 16S ribosomal RNA gene, partial sequence-
X95624.1) 
 
 
 
 
 
 
 Bibliography 
 [1]Spor et al.(2011)Nat Rev Microbiol.9(4):279-90. 
 [2]Tap et al.(2009),Environ Microbiol,11(10):2574-84 
 [3]Macpherson et al.(2001)Microbes Infect.3(12):1021-35 
 [4]Macpherson et al.(2002)Cell Mol Life Sci.59(12):2088-96. 
 [5]Mazmanian et al.(2005)Cell 15Ôºõ122(1):107-18. 
 [6]Frank et al.(2007)PNAS 104(34):13780-5. 
 [7]Scanlan et al.(2006)J Clin Microbiol.44(11):3980-8. 
 [8]Kang et al.(2010)Inflamm Bowel Dis.16(12):2034-42. 
 [9]Machiels et al.(2013)Gut.63(8):1275-83. 
 [10]WO 2013/050792 
 [11]WO 03/046580 
 [12]WO 2013/008039 
 [13]WO 2014/167338 
 [14]Lee and Lee(2014)World J Gastroenterol.20(27):8886-8897. 
 [15]Xie et al.(2016)Journal Dairy Sci.99:6913‚Äì6921 
 [16]WO 01/85187 
 [17]WO2016/086161 
 [18]YQ et al.(2016),J.Dig.Dis.,‚ÄúTherapeutic Modulation of the Gut
Microbiota in IBD-More Questions to Be Answered‚Äù,Oct 15, 1751-2980,12422,Epub
ahead of print. 
 [19]Lozupone(2012).Nature.2012 September 13Ôºõ489(7415): 220‚Äì230 
 [20]Claesson,et al.(2012)Nature,488,178-184. 
 [21]Hansen,et al.,(2010),Curr.Opin.Gastroenterol.,26(6): 564-571. 
 [22]Turnbaugh et al.Nature,457(7228):480-484. 
 [23]Wang et al.(2009)ISME J.3(8):944-954. 
 [24]Faith et al.(2013),Science,341(6141):1237439 
 [25]Liu et al.(2008)Int J Syst Evol Microbiol 58,1896‚Äì1902. 
 [26]Bernalier et al.(1996)Arch.Microbiol.166(3),176-183. 
 [27]Park et al.(2012)Int J Syst Evol Microbiol.62(Pt 4):776-9. 
 [28]Masco et al.(2003)Systematic and Applied Microbiology, 26:557-
563. 
 [29] et al.(2011)J.Microbiol.Methods,87(1):10-6. 
 [30]Miyamoto-Shinohara et al.(2008)J.Gen.Appl.Microbiol.,54, 9‚Äì24. 
 [31]Cryopreservation and Freeze-Drying Protocols,ed.by Day and
McLellan,Humana Press. 
 [32]Leslie et al.(1995)Appl.Environ.Microbiol.61,3592‚Äì3597. 
 [33]Mitropoulou et al.(2013)J Nutr Metab.(2013)716861. 
 [34]Kailasapathy et al.(2002)Curr Issues Intest Microbiol. 3(2):39-
48. 
 [35]Handbook of Pharmaceutical Excipients,2nd Edition,(1994), Edited
by A Wade and PJ Weller 
 [36]Remington's Pharmaceutical Sciences,Mack Publishing Co.(A.
R.Gennaro edit.1985) 
 [37]US 2016/0067188 
 [38]Handbook of Microbiological Media,Fourth Edition(2010) Ronald
Atlas,CRC Press. 
 [39]Maintaining Cultures for Biotechnology and Industry(1996) Jennie
C.Hunter-Cevera,Academic Press 
 [40]Strobel(2009)Methods Mol Biol.581:247-61. 
 [41]Gennaro(2000)Remington:The Science and Practice of Pharmacy.20th
edition,ISBN:0683306472. 
 [42]Molecular Biology Techniques:An Intensive Laboratory Course,(Ream
et al.,eds.,1998,Academic Press). 
 [43]Methods In Enzymology(S.Colowick and N.Kaplan,eds., Academic
Press,Inc.) 
 [44]Handbook of Experimental Immunology,Vols.I-IV(D.M.Weir and
C.C.Blackwell,eds,1986,Blackwell Scientific Publications) 
 [45]Sambrook et al.(2001)Molecular Cloning:A Laboratory Manual,3rd
edition(Cold Spring Harbor Laboratory Press). 
 [46]Handbook of Surface and Colloidal Chemistry(Birdi,K.S.ed., CRC
Press,1997) 
 [47]Ausubel et al.(eds)(2002)Short protocols in molecular biology,5th
edition(Current Protocols). 
 [48]PCR(Introduction to Biotechniques Series),2nd ed.(Newton& Graham
eds.,1997,Springer Verlag) 
 [49]Current Protocols in Molecular Biology(F.M.Ausubel et al., eds.,
1987)Supplement 30 
 [50]Smith&Waterman(1981)Adv.Appl.Math.2:482-489. 
 [51]Meyza and Blanchard(2017)Neurosci Biobehav Rev.Ôºõ76(Pt A):99-110 
 [52]Constantinescu et al.(2011)Br J Pharmacol. 164(4):1079‚Äì1106 
 Sequence table 
 <110>4D pharmaceutical Co. Ltd (4D Pharma PLC) 
 <120>comprising the composition of bacterium bacterial strain 
 <130> P069516WO 
 <141> 2017-12-12 
 <150> GB1621123.7 
 <151> 2016-12-12 
 <160> 5 
 <170> SIPOSequenceListing 1.0 
 <210> 1 
 <211> 1372 
 <212> DNA 
 <213>excrement Blaw spy Salmonella (Blautia stercoris) 
 <400> 1 
 tgcaagtcga gcgaagcgct tacgacagaa ccttcggggg aagatgtaag ggactgagcg 60 
 gcggacgggt gagtaacgcg tgggtaacct gcctcataca gggggataac agttggaaac 120 
 ggctgctaat accgcataag cgcacggtat cgcatgatac agtgtgaaaa actccggtgg 180 
 tatgagatgg acccgcgtct gattagctag ttggaggggt aacggcccac caaggcgacg 240 
 atcagtagcc ggcctgagag ggtgaacggc cacattggga ctgagacacg gcccagactc 300 
 ctacgggagg cagcagtggg gaatattgca caatggggga aaccctgatg cagcgacgcc 360 
 gcgtgaagga agaagtatct cggtatgtaa acttctatca gcagggaaga aaatgacggt 420 
 acctgactaa gaagccccgg ctaactacgt gccagcagcc gcggtaatac gtagggggca 480 
 agcgttatcc ggatttactg ggtgtaaagg gagcgtagac ggaagagcaa gtctgatgtg 540 
 aaaggctggg gcttaacccc aggactgcat tggaaactgt ttttcttgag tgccggagag 600 
 gtaagcggaa ttcctagtgt agcggtgaaa tgcgtagata ttaggaggaa caccagtggc 660 
 gaaggcggct tactggacgg taactgacgt tgaggctcga aagcgtgggg agcaaacagg 720 
 attagatacc ctggtagtcc acgccgtaaa cgatgaatac taggtgttgg ggagcaaagc 780 
 tcttcggtgc cgcagcaaac gcaataagta ttccacctgg ggagtacgtt cgcaagaatg 840 
 aaactcaaag gaattgacgg ggacccgcac aagcggtgga gcatgtggtt taattcgaag 900 
 caacgcgaag aaccttacca agtcttgaca tcgatctgac cggttcgtaa tggaaccttt 960 
 ccttcgggac agagaagaca ggtggtgcat ggttgtcgtc agctcgtgtc gtgagatgtt 1020 
 gggttaagtc ccgcaacgag cgcaacccct atcctcagta gccagcaggt gaagctgggc 1080 
 actctgtgga gactgccagg gataacctgg aggaaggcgg ggacgacgtc aaatcatcat 1140 
 gccccttatg atttgggcta cacacgtgct acaatggcgt aaacaaaggg aagcgagccc 1200 
 gcgaggggga gcaaatccca aaaataacgt cccagttcgg actgcagtct gcaactcgac 1260 
 tgcacgaagc tggaatcgct agtaatcgcg aatcagaatg tcgcggtgaa tacgttcccg 1320 
 ggtcttgtac acaccgcccg tcacaccatg ggagtcagta acgcccgaag tc 1372 
 <210> 2 
 <211> 1438 
 <212> DNA 
 <213>Webster Blaw spy Salmonella (Blautia wexlerae) 
 <220> 
 <221> misc_feature 
 <222> (19) 
 <223>' n' is a, c, g or t 
 <220> 
 <221> misc_feature 
 <222> (19) 
 <223>' n' is a, c, g or t 
 <400> 2 
 caagtcgaac gggaattant ttattgaaac ttcggtcgat ttaatttaat tctagtggcg 60 
 gacgggtgag taacgcgtgg gtaacctgcc ttatacaggg ggataacagt cagaaatggc 120 
 tgctaatacc gcataagcgc acagagctgc atggctcagt gtgaaaaact ccggtggtat 180 
 aagatggacc cgcgttggat tagcttgttg gtggggtaac ggcccaccaa ggcgacgatc 240 
 catagccggc ctgagagggt gaacggccac attgggactg agacacggcc cagactccta 300 
 cgggaggcag cagtggggaa tattgcacaa tgggggaaac cctgatgcag cgacgccgcg 360 
 tgaaggaaga agtatctcgg tatgtaaact tctatcagca gggaagatag tgacggtacc 420 
 tgactaagaa gccccggcta actacgtgcc agcagccgcg gtaatacgta gggggcaagc 480 
 gttatccgga tttactgggt gtaaagggag cgtagacggt gtggcaagtc tgatgtgaaa 540 
 ggcatgggct caacctgtgg actgcattgg aaactgtcat acttgagtgc cggaggggta 600 
 agcggaattc ctagtgtagc ggtgaaatgc gtagatatta ggaggaacac cagtggcgaa 660 
 ggcggcttac tggacggtaa ctgacgttga ggctcgaaag cgtggggagc aaacaggatt 720 
 agataccctg gtagtccacg ccgtaaacga tgaataacta ggtgtcgggt ggcaaagcca 780 
 ttcggtgccg tcgcaaacgc agtaagtatt ccacctgggg agtacgttcg caagaatgaa 840 
 actcaaagga attgacgggg acccgcacaa gcggtggagc atgtggttta attcgaagca 900 
 acgcgaagaa ccttaccaag tcttgacatc cgcctgaccg atccttaacc ggatctttcc 960 
 ttcgggacag gcgagacagg tggtgcatgg ttgtcgtcag ctcgtgtcgt gagatgttgg 1020 
 gttaagtccc gcaacgagcg caacccctat cctcagtagc cagcatttaa ggtgggcact 1080 
 ctggggagac tgccagggat aacctggagg aaggcgggga tgacgtcaaa tcatcatgcc 1140 
 ccttatgatt tgggctacac acgtgctaca atggcgtaaa caaagggaag cgagattgtg 1200 
 agatggagca aatcccaaaa ataacgtccc agttcggact gtagtctgca acccgactac 1260 
 acgaagctgg aatcgctagt aatcgcggat cagaatgccg cggtgaatac gttcccgggt 1320 
 cttgtacaca ccgcccgtca caccatggga gtcagtaacg cccgaagtca gtgacctaac 1380 
 tgcaaagaag gagctgccga aggcgggacc gatgactggg gtgaagtcgt aacaaggt 1438 
 <210> 3 
 <211> 1481 
 <212> DNA 
 <213>artificial sequence (Artificial Sequence) 
 <220> 
 <221> gene 
 <222> ()..() 
 <223>the shared 16s of excrement Blaw spy Salmonella 
 <400> 3 
 tttkgtctgg ctcaggatga acgctggcgg cgtgcttaac acatgcaagt cgagcgaagc 60 
 gcttacgaca gaaccttcgg gggaagatgt aagggactga gcggcggacg ggtgagtaac 120 
 gcgtgggtaa cctgcctcat acagggggat aacagttgga aacggctgct aataccgcat 180 
 aagcgcacag tatcgcatga tacagtgtga aaaactccgg tggtatgaga tggacccgcg 240 
 tctgattagc tagttggagg ggtaacggcc caccaaggcg acgatcagta gccggcctga 300 
 gagggtgaac ggccacattg ggactgagac acggcccaga ctcctacggg aggcagcagt 360 
 ggggaatatt gcacaatggg ggaaaccctg atgcagcgac gccgcgtgaa ggaagaagta 420 
 tctcggtatg taaacttcta tcagcaggga agaaaatgac ggtacctgac taagaagccc 480 
 cggctaacta cgtgccagca gccgcggtaa tacgtagggg gcaagcgtta tccggattta 540 
 ctgggtgtaa agggagcgta gacggaagag caagtctgat gtgaaaggct ggggcttaac 600 
 cccaggactg cattggaaac tgtttttctt gagtgccgga gaggtaagcg gaattcctag 660 
 tgtagcggtg aaatgcgtag atattaggag gaacaccagt ggcgaaggcg gcttactgga 720 
 cggtaactga cgttgaggct cgaaagcgtg gggagcaaac aggattagat accctggtag 780 
 tccacgccgt aaacgatgaa tactaggtgt tggggagcaa agctcttcgg tgccgcagca 840 
 aacgcaataa gtattccacc tggggagtac gttcgcaaga atgaaactca aaggaattga 900 
 cggggacccg cacaagcggt ggagcatgtg gtttattcga agcaacgcga agaaccttac 960 
 caagtcttga catcgatctg accggttcgt aatggaacct ttccttcggg acagagaaga 1020 
 caggtggtgc atggttgtcg tcagctcgtg tcgtgagatg ttgggttaag tcccgcaacg 1080 
 agcgcaaccc ctatcgtcag tagccagcag gtaaagctgg gcactctgag gagactgcca 1140 
 gggataacct ggaggaaggc ggggacgacg tcaaatcatc atgcccctta tgatttgggc 1200 
 tacacacgtg ctacaatggc gtaaacaaag ggaagcgagc ccgcgagggg gagcaaatcc 1260 
 caaaaataac gtcccagttc ggactgcagt ctgcaactcg actgcacgaa gctggaatcg 1320 
 ctagtaatcg cgaatcagaa tgtcgcggtg aatacgttcc cgggtcttgt acacaccgcc 1380 
 cgtcacacca tgggagtcag taacgcccga agtcagtgac ccaaccttag ggagggagct 1440 
 gccgaaggcg ggattgataa ctggggtgaa gtctaggggg t 1481 
 <210> 4 
 <211> 1384 
 <212> DNA 
 <213>artificial sequence (Artificial Sequence) 
 <220> 
 <221> gene 
 <222> ()..() 
 <223>the shared 16s of Webster Blaw spy Salmonella 
 <220> 
 <221> misc_feature 
 <222> (749) 
 <223>' n' is a, c, g or t 
 <220> 
 <221> misc_feature 
 <222> (749) 
 <223>' n' is a, c, g or t 
 <400> 4 
 ttcattgaga cttcggtgga tttagattct atttctagtg gcggacgggt gagtaacgcg 60 
 tgggtaacct gccttataca gggggataac agtcagaaat ggctgctaat accgcataag 120 
 cgcacagagc tgcatggctc agtgtgaaaa actccggtgg tataagatgg acccgcgttg 180 
 gattagcttg ttggtggggt aacggcccac caaggcgacg atccatagcc ggcctgagag 240 
 ggtgaacggc cacattggga ctgagacacg gcccagactc ctacgggagg cagcagtggg 300 
 gaatattgca caatggggga aaccctgatg cagcgacgcc gcgtgaagga agaagtatct 360 
 cggtatgtaa acttctatca gcagggaaga tagtgacggt acctgactaa gaagccccgg 420 
 ctaactacgt gccagcagcc gcggtaatac gtagggggca agcgttatcc ggatttactg 480 
 ggtgtaaagg gagcgtagac ggtgtggcaa gtctgatgtg aaaggcatgg gctcaacctg 540 
 tggactgcat tggaaactgt catacttgag tgccggaggg gtaagcggaa ttcctagtgt 600 
 agcggtgaaa tgcgtagata ttaggaggaa caccagtggc gaaggcggct tactggacgg 660 
 taactgacgt tgaggctcga aagcgtgggg agcaaacagg attagatacc ctggtagtcc 720 
 acgccgtaaa cgatgaatac taggtgtcng gggagcatgg ctcttcggtg ccgtcgcaaa 780 
 cgcagtaagt attccacctg gggagtacgt tcgcaagaat gaaactcaaa ggaattgacg 840 
 gggacccgca caagcggtgg agcatgtggt ttaattcgaa gcaacgcgaa gaaccttacc 900 
 aagtcttgac atccgcctga ccgatcctta accggatctt tccttcggga caggcgagac 960 
 aggtggtgca tggttgtcgt cagctcgtgt cgtgagatgt tgggttaagt cccgcaacga 1020 
 gcgcaacccc tatcctcagt agccagcatt taaggtgggc actctgggga gactgccagg 1080 
 gataacctgg aggaaggcgg ggatgacgtc aaatcatcat gccccttatg atttgggcta 1140 
 cacacgtgct acaatggcgt aaacaaaggg aagcgagatc gtgagatgga gcaaatccca 1200 
 aaaataacgt cccagttcgg actgtagtct gcaacccgac tacacgaagc tggaatcgct 1260 
 agtaatcgcg gatcagaatg ccgcggtgaa tacgttcccg ggtcttgtac acaccgcccg 1320 
 tcacaccatg ggagtcagta acgcccgaag tcagtgacct aactgcaaag aaggagctgc 1380 
 cgaa 1384 
 <210> 5 
 <211> 1458 
 <212> DNA 
 <213>hydrogen nutrition Blaw spy Salmonella (Blautia hydrogenotrophica) 
 <220> 
 <221> misc_feature 
 <222> (1416) 
 <223>' n' is a, c, g or t 
 <220> 
 <221> misc_feature 
 <222> (1416) 
 <223>' n' is a, c, g or t 
 <400> 5 
 gatgaacgct ggcggcgtgc ttaacacatg caagtcgaac gaagcgatag agaacggaga 60 
 tttcggttga agttttctat tgactgagtg gcggacgggt gagtaacgcg tgggtaacct 120 
 gccctataca gggggataac agttagaaat gactgctaat accgcataag cgcacagctt 180 
 cgcatgaagc ggtgtgaaaa actgaggtgg tataggatgg acccgcgttg gattagctag 240 
 ttggtgaggt aacggcccac caaggcgacg atccatagcc ggcctgagag ggtgaacggc 300 
 cacattggga ctgagacacg gcccaaactc ctacgggagg cagcagtggg gaatattgca 360 
 caatggggga aaccctgatg cagcgacgcc gcgtgaagga agaagtatct cggtatgtaa 420 
 acttctatca gcagggaaga aagtgacggt acctgactaa gaagccccgg ctaattacgt 480 
 gccagcagcc gcggtaatac gtaaggggca agcgttatcc ggatttactg ggtgtaaagg 540 
 gagcgtagac ggtttggcaa gtctgatgtg aaaggcatgg gctcaacctg tggactgcat 600 
 tggaaactgt cagacttgag tgccggagag gcaagcggaa ttcctagtgt agcggtgaaa 660 
 tgcgtagata ttaggaggaa caccagtggc gaaggcggcc tgctggacgg taactgacgt 720 
 tgaggctcga aagcgtgggg agcaaacagg attagatacc ctggtagtcc acgctgtaaa 780 
 cgatgaatac taggtgtcgg gtggcaaagc cattcggtgc cgcagcaaac gcaataagta 840 
 ttcccacctg gggagtacgt tcgcaagaat gaaactcaaa ggaattgacg gggacccgca 900 
 caagcggtgg agcatgtggt ttaattcgaa gcaacgcgaa gaaccttacc aaatcttgac 960 
 atccctctga ccgggaagta atgttccctt ttcttcggaa cagaggagac aggtggtgca 1020 
 tggttgtcgt cagctcgtgt cgtgagatgt tgggttaagt cccgcaacga gcgcaaccct 1080 
 tattcttagt agccagcagg tagagctggg cactctaggg agactgccag ggataacctg 1140 
 gaggaaggtg gggatgacgt caaatcatca tgccccttat gatttgggct acacacgtgc 1200 
 tacaatggcg taaacaaagg gaagcgaagg ggtgacctgg agcaaatctc aaaaataacg 1260 
 tctcagttcg gattgtagtc tgcaactcga ctacatgaag ctggaatcgc tagtaatcgc 1320 
 gaatcagaat gtcgcggtga atacgttccc gggtcttgta cacaccgccc gtcacaccat 1380 
 gggagtcagt aacgcccgaa gtcagtgacc caaccnaaag gagggagctg ccgaaggtgg 1440 
 gactgataac tggggtga 1458 
 
 
 
 
 
 
 
 
 
 
